1170 lines
229 KiB
Text
1170 lines
229 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK7014">
|
|
<meta name="ncbi_domain" content="gene">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK7014/?report=reader">
|
|
<meta name="ncbi_pagename" content="Von Willebrand Disease - GeneReviews® - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Von Willebrand Disease - GeneReviews® - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/gene/vhl/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/gene/wac-id/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/gene/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="GeneReviews® [Internet]">
|
|
<meta name="citation_title" content="Von Willebrand Disease">
|
|
<meta name="citation_publisher" content="University of Washington, Seattle">
|
|
<meta name="citation_date" content="2024/11/14">
|
|
<meta name="citation_author" content="Jill Johnsen">
|
|
<meta name="citation_pmid" content="20301765">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK7014/">
|
|
<meta name="citation_keywords" content="Von Willebrand Factor Deficiency">
|
|
<meta name="citation_keywords" content="Type 1 Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="Type 2A Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="Type 2B Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="Type 2M Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="Type 2N Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="Type 3 Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="Type 1C Von Willebrand Disease">
|
|
<meta name="citation_keywords" content="von Willebrand factor">
|
|
<meta name="citation_keywords" content="VWF">
|
|
<meta name="citation_keywords" content="Von Willebrand Disease">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Von Willebrand Disease">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="University of Washington, Seattle">
|
|
<meta name="DC.Contributor" content="Jill Johnsen">
|
|
<meta name="DC.Date" content="2024/11/14">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK7014/">
|
|
<meta name="description" content="Von Willebrand disease (VWD) is characterized by mucocutaneous bleeding and excessive bleeding with trauma and procedures. Individuals with more severe forms of VWD are also at-risk for musculoskeletal bleeding. Mucocutaneous bleeding can include easy bruising, prolonged bleeding from minor wounds, epistaxis, oral cavity bleeding, heavy menstrual bleeding, gastrointestinal bleeding, and bleeding with hemostatic challenges such as dental work, childbirth, and surgery. Bleeding severity can vary widely in VWD, even between affected individuals within the same family. For some with VWD the bleeding phenotype may only become apparent upon hemostatic challenge, while others may have frequent spontaneous bleeding.">
|
|
<meta name="og:title" content="Von Willebrand Disease">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Von Willebrand disease (VWD) is characterized by mucocutaneous bleeding and excessive bleeding with trauma and procedures. Individuals with more severe forms of VWD are also at-risk for musculoskeletal bleeding. Mucocutaneous bleeding can include easy bruising, prolonged bleeding from minor wounds, epistaxis, oral cavity bleeding, heavy menstrual bleeding, gastrointestinal bleeding, and bleeding with hemostatic challenges such as dental work, childbirth, and surgery. Bleeding severity can vary widely in VWD, even between affected individuals within the same family. For some with VWD the bleeding phenotype may only become apparent upon hemostatic challenge, while others may have frequent spontaneous bleeding.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK7014/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/gene/von-willebrand/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK7014/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D95837C8B26F100000000006A0058.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK7014/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/gene/vhl/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Von Willebrand Disease</div><div class="j">GeneReviews® [Internet]</div></div><div class="tail"><a href="/books/n/gene/wac-id/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK7014/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK7014/&text=Von%20Willebrand%20Disease"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/gene/?report=reader">Title Information</a><a href="/books/n/gene/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK7014/?report=classic">Switch to classic view</a><a href="/books/NBK7014/pdf/Bookshelf_NBK7014.pdf">PDF (849K)</a><a href="/books/NBK7014/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK7014%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D95837C8B26F100000000006A0058.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK7014_"><span class="title" itemprop="name">Von Willebrand Disease</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Von Willebrand Factor Deficiency</div><p class="contribs">Johnsen J.</p><p class="fm-aai"><a href="#_NBK7014_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 47 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="von-willebrand.Summary" itemprop="description"><h2 id="_von-willebrand_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Von Willebrand disease (VWD) is characterized by mucocutaneous bleeding and excessive bleeding with trauma and procedures. Individuals with more severe forms of VWD are also at-risk for musculoskeletal bleeding. Mucocutaneous bleeding can include easy bruising, prolonged bleeding from minor wounds, epistaxis, oral cavity bleeding, heavy menstrual bleeding, gastrointestinal bleeding, and bleeding with hemostatic challenges such as dental work, childbirth, and surgery. Bleeding severity can vary widely in VWD, even between affected individuals within the same family. For some with VWD the bleeding phenotype may only become apparent upon hemostatic challenge, while others may have frequent spontaneous bleeding.</p></div><div><h4 class="inline">Diagnosis.</h4><p>The diagnosis of VWD is established in a proband with excessive bleeding by identification of a quantitative or qualitative deficiency in von Willebrand factor (VWF) and/or identification of a VWD-causative variant(s) in <i>VWF</i> by molecular genetic testing.</p></div><div><h4 class="inline">Management.</h4><p><i>Targeted therapy:</i> VWF replacement; desmopressin.</p><p><i>Supportive care:</i> People with VWD benefit from care in a comprehensive bleeding disorders program. Treatment is often given on demand for active bleeding episodes or for prevention of bleeding with hemostatic challenges. Prophylaxis should be considered in those with more severe bleeding. Useful adjunctive hemostatic treatments include antifibrinolytics, hormonal therapies for female reproductive tract bleeding, and local anatomic measures. Antifibrinolytic treatment (e.g., tranexamic acid) can be used alone for some hemostatic challenges or in combination with VWF-increasing treatment. Hormonal treatments can be useful in managing female reproductive tract bleeding either alone or in combination with antifibrinolytics and/or VWD-specific treatment.</p><p><i>Surveillance:</i> Assessment in a center experienced in the comprehensive management of bleeding disorders to determine bleeding frequency and severity, treatment efficacy and tolerability, CBC, iron levels, VWF levels, and VWF inhibitors in those at risk (type 3 VWD) annually in those receiving treatment or every two to three years in those without bleeding and not requiring treatment. Evaluation by a physiotherapist, including consideration of musculoskeletal ultrasound evaluation for those with more severe VWD and/or low factor VIII levels, to monitor joint health (as in individuals with hemophilia A). Gynecology evaluation as needed for females with heavy bleeding. Gastroenterology evaluation with any suspected gastrointestinal bleeding or per gastroenterologist. Infectious disease assessment as needed in those exposed to blood products prior to 1985 or with other risk factors.</p><p><i>Agents/circumstances to avoid:</i> Activities with a high risk of trauma; high contact sports with risk of head injury; medications with effects on platelet function (e.g., aspirin, clopidogrel); nutritional supplements that may impair hemostasis (e.g., fish oil, turmeric); invasive procedures without prior consultation with a hematologist (e.g., circumcision, dental, dermatologic, piercings). NSAIDs can increase bleeding risk and should be used cautiously and only for brief periods.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate apparently asymptomatic at-risk relatives of an affected individual to allow early diagnosis and treatment as needed. In newborns, assess cord blood for low VWF and factor VIII levels to inform neonatal treatment. Molecular genetic testing of cord blood can be informative, particularly if the familial VWD-causing variant(s) are known.</p><p><i>Pregnancy management:</i> Monitor VWF and factor VIII levels throughout pregnancy; postpartum hemorrhage prophylaxis with antifibrinolytics unless contraindicated; VWF replacement can be used to increase VWF levels.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Type 1, type 2A, and type 2M VWD are typically caused by a heterozygous <i>VWF</i> variant and inherited in an autosomal dominant manner; rarely, these VWD types are associated with biallelic <i>VWF</i> variants. Type 2B VWD is typically caused by a heterozygous <i>VWF</i> variant and inherited in an autosomal dominant manner. Type 2N and type 3 VWD are caused by biallelic <i>VWF</i> variants and inherited in an autosomal recessive manner.</p><p><i>Autosomal dominant inheritance:</i> Many individuals diagnosed with autosomal dominant VWD have an affected parent. Each child of an individual with autosomal dominant VWD has a 50% chance of inheriting the VWD-causing variant. VWD often exhibits variable penetrance and expressivity.</p><p><i>Autosomal recessive inheritance:</i> If both parents are known to be heterozygous for a VWD-causing variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial VWD-causing variants. Heterozygous sibs of an individual with type 2N VWD are often asymptomatic; however, a small proportion of these heterozygous individuals may have some mild bleeding symptoms and lower factor VIII levels and may be diagnosed with VWD. Heterozygous sibs of an individual with type 3 VWD may be asymptomatic or may have bleeding symptoms and low VWF levels and may be diagnosed with type 1 VWD. Molecular genetic testing for at-risk relatives is most informative if the VWD-causing variant(s) have been identified in an affected family member.</p><p>Once the familial VWD-causing variant(s) have been identified, prenatal and preimplantation genetic testing for VWD are possible.</p></div></div><div id="von-willebrand.GeneReview_Scope"><h2 id="_von-willebrand_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTvonwillebranddisease"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobvonwillebrandTvonwillebranddisease"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.von_willebrand_disease"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease">Table</a></h4><p class="float-caption no_bottom_margin">Von Willebrand Disease: Phenotypic Spectrum </p></div></div></div><div id="von-willebrand.Diagnosis"><h2 id="_von-willebrand_Diagnosis_">Diagnosis</h2><p>International guidelines on the diagnosis of von Willebrand disease (VWD) have been published [<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al 2021</a>].</p><div id="von-willebrand.Suggestive_Findings"><h3>Suggestive Findings</h3><p>VWD <b>should be suspected</b> in probands with the following clinical and laboratory findings.</p><p>
|
|
<b>Clinical findings</b>
|
|
</p><ul><li class="half_rhythm"><div>Excessive bruising, particularly without recognized trauma</div></li><li class="half_rhythm"><div>Prolonged bleeding from cutaneous wounds</div></li><li class="half_rhythm"><div>Prolonged, recurrent, and/or severe nosebleeds</div></li><li class="half_rhythm"><div>Bleeding from the gums after brushing or flossing teeth, particularly lifelong or in the absence of periodontal disease, and/or prolonged bleeding following dental cleaning or dental extractions</div></li><li class="half_rhythm"><div>Excessive female reproductive tract bleeding including uterine bleeding (e.g., heavy menstrual bleeding, postpartum hemorrhage) and ovarian hemorrhage</div></li><li class="half_rhythm"><div>Prolonged bleeding following invasive procedures, surgery, or trauma</div></li><li class="half_rhythm"><div>Excessive gastrointestinal bleeding, or gastrointestinal bleeding with angiodysplasia</div></li><li class="half_rhythm"><div>More severe forms may develop hemarthrosis and/or hemarthropathy</div></li></ul><p>
|
|
<b>Routine laboratory findings</b>
|
|
</p><ul><li class="half_rhythm"><div><b>Complete blood count (CBC)</b> is often normal but may show microcytic anemia (in those with iron deficiency) or thrombocytopenia in those with type 2B VWD. In type 2B VWD, thrombocytopenia is accompanied by platelet clumping that can be seen on blood smear.</div></li><li class="half_rhythm"><div><b>Activated partial thromboplastin time (aPTT)</b> is often normal but may be prolonged when the factor VIII clotting activity level (FVIII:C) is low (i.e., <20-30 IU/dL), as can be seen in some individuals with type 1 and type 2 VWD, and in all individuals with type 2N and type 3 VWD.</div></li><li class="half_rhythm"><div><b>Prothrombin time</b> is normal.</div></li></ul></div><div id="von-willebrand.Establishing_the_Diagnosi"><h3>Establishing the Diagnosis</h3><p>The diagnosis of VWD <b>can be established</b> in a proband with excessive bleeding by identification of one of the following (see <a class="figpopup" href="/books/NBK7014/figure/von-willebrand.F1/?report=objectonly" target="object" rid-figpopup="figvonwillebrandF1" rid-ob="figobvonwillebrandF1">Figure 1</a>):</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figvonwillebrandF1" co-legend-rid="figlgndvonwillebrandF1"><a href="/books/NBK7014/figure/von-willebrand.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figvonwillebrandF1" rid-ob="figobvonwillebrandF1"><img class="small-thumb" src="/books/NBK7014/bin/von-willebrand-Image001.gif" src-large="/books/NBK7014/bin/von-willebrand-Image001.jpg" alt="Figure 1. . An approach to the diagnosis of von Willebrand disease (VWD) [James et al 2021]." /></a><div class="icnblk_cntnt" id="figlgndvonwillebrandF1"><h4 id="von-willebrand.F1"><a href="/books/NBK7014/figure/von-willebrand.F1/?report=objectonly" target="object" rid-ob="figobvonwillebrandF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">An approach to the diagnosis of von Willebrand disease (VWD) [James et al 2021]. VWF levels refer to VWF antigen (VWF:Ag) and/or platelet-dependent VWF activity of 30-50 IU/dL, with the caveat that the laboratory’s lower limit of the normal range <a href="/books/NBK7014/figure/von-willebrand.F1/?report=objectonly" target="object" rid-ob="figobvonwillebrandF1">(more...)</a></p></div></div><ul><li class="half_rhythm"><div>Decreased quantity of von Willebrand factor (VWF)</div></li><li class="half_rhythm"><div>Qualitative defect in VWF identified on a VWF activity assay or VWF multimer gel</div></li><li class="half_rhythm"><div>VWD-causative variant(s) in <i>VWF</i> by molecular genetic testing</div></li></ul><p>Note: Additional testing can inform VWD type (see <a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclassificationofvwdb">Table 1</a> and <a class="figpopup" href="/books/NBK7014/figure/von-willebrand.F2/?report=objectonly" target="object" rid-figpopup="figvonwillebrandF2" rid-ob="figobvonwillebrandF2">Figure 2</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figvonwillebrandF2" co-legend-rid="figlgndvonwillebrandF2"><a href="/books/NBK7014/figure/von-willebrand.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figvonwillebrandF2" rid-ob="figobvonwillebrandF2"><img class="small-thumb" src="/books/NBK7014/bin/von-willebrand-Image002.gif" src-large="/books/NBK7014/bin/von-willebrand-Image002.jpg" alt="Figure 2. . Algorithms for additional testing in suspected type 2B von Willebrand disease (VWD) (left) and suspected type 2N VWD (right)." /></a><div class="icnblk_cntnt" id="figlgndvonwillebrandF2"><h4 id="von-willebrand.F2"><a href="/books/NBK7014/figure/von-willebrand.F2/?report=objectonly" target="object" rid-ob="figobvonwillebrandF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Algorithms for additional testing in suspected type 2B von Willebrand disease (VWD) (left) and suspected type 2N VWD (right). GPIb = glycoprotein Ib; RIPA = ristocetin-induced platelet agglutination; VWF:FVIII = von Willebrand factor/Factor VIII ratio. <a href="/books/NBK7014/figure/von-willebrand.F2/?report=objectonly" target="object" rid-ob="figobvonwillebrandF2">(more...)</a></p></div></div><p><b>VWD laboratory assays</b> (see <a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclassificationofvwdb">Table 1</a>) [<a class="bibr" href="#von-willebrand.REF.bod_.2015.1345" rid="von-willebrand.REF.bod_.2015.1345">Bodó et al 2015</a>, <a class="bibr" href="#von-willebrand.REF.kalot.2022a.3735" rid="von-willebrand.REF.kalot.2022a.3735">Kalot et al 2022a</a>]</p><ul><li class="half_rhythm"><div><b>VWF:Ag.</b> Decreased quantity of VWF protein (antigen) measured using ELISA or latex immunoassay can be identified in individuals with type 1 VWD and in some individuals with type 2 VWD. VWF:Ag is undetectable in individuals with type 3 VWD (see <a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclassificationofvwdb">Table 1</a>) [<a class="bibr" href="#von-willebrand.REF.castaman.2010.227" rid="von-willebrand.REF.castaman.2010.227">Castaman et al 2010</a>].</div></li><li class="half_rhythm"><div>
|
|
<b>Platelet-dependent VWF activity assays</b>
|
|
</div><ul><li class="half_rhythm"><div><b>VWF:GPIbR.</b> Assay that tests ristocetin-induced binding of VWF to glycoprotein Ib (GPIb). Decreased binding activity can be identified in individuals with most types of VWD. The results of this assay can be artifactually low in individuals with benign <i>VWF</i> variants that interfere with the ristocetin-VWF interaction.</div></li><li class="half_rhythm"><div><b>VWF:GPIbM.</b> Assay that tests the binding of VWF to a GPIb fragment with a gain-of-function variant. Decreased binding activity can be identified in individuals with most types of VWD. This assay does not use ristocetin.</div></li><li class="half_rhythm"><div><b>VWF:RCo.</b> Ristocetin cofactor activity assay that uses reagent platelets and ristocetin to test the ability of VWF to agglutinate platelets. This assay can have a high coefficient of variation. Individuals with a benign <i>VWF</i> variant that interferes with ristocetin can have artifactually low results. Decreased VWF:RCo activity can be identified in individuals with most types of VWD. Current guidance recommends using newer platelet-dependent VWF activity assays instead of ristocetin-based assays [<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al 2021</a>].</div></li></ul></li><li class="half_rhythm"><div><b>Factor VIII (FVIII) activity</b> assays used in individuals with VWD include either the one-stage FVIII activity assay or the chromogenic FVIII activity assay. FVIII activity is always low in type 2N and type 3 VWD and is often low in most other forms of VWD.</div></li></ul><p>
|
|
<b>Assays to inform the type of VWD</b>
|
|
</p><ul><li class="half_rhythm"><div><b>VWF multimer analysis.</b> SDS-agarose gel electrophoresis is used to determine the distribution of sizes of VWF multimers. Normal plasma contains VWF complexes ranging from VWF dimers to very large VWF multimers (500 kD to >10,000 kD). Multimers are classified as low (1-5 bands), intermediate (6-9 bands), and high (≥10 bands) molecular weight. High-molecular-weight multimers are decreased or absent in all individuals with type 2A VWD and many with type 2B VWD; intermediate- and low-molecular-weight multimers may also be decreased or absent in individuals with type 2A or type 2B VWD. Abnormalities detected in VWF multimer satellite ("triplet") band patterns can give clues as to the underlying pathogenesis of the VWD [<a class="bibr" href="#von-willebrand.REF.budde.2008.762" rid="von-willebrand.REF.budde.2008.762">Budde et al 2008</a>, <a class="bibr" href="#von-willebrand.REF.stockschlaeder.2014.206" rid="von-willebrand.REF.stockschlaeder.2014.206">Stockschlaeder et al 2014</a>]. However, protocols that can detect VWF triplet band multimer patterns are not available in all clinical laboratories that do multimer assays.</div></li><li class="half_rhythm"><div><b>Ristocetin-induced platelet agglutination (RIPA)</b> can assess the ability of VWF to agglutinate platelets in platelet-rich plasma in the presence of specific concentrations of ristocetin. Agglutination at a low ristocetin concentration (~0.5-0.7 mg/mL) or spontaneous agglutination in the absence of ristocetin indicates enhanced VWF platelet binding due to either type 2B VWD or platelet-type VWD (see <a href="#von-willebrand.Differential_Diagnosis">Differential Diagnosis</a>).</div></li><li class="half_rhythm"><div><b>VWF:FVIIIB.</b> A functional assay that measures the ability of VWF to bind reagent FVIII. Binding is decreased in individuals with type 2N VWD.</div></li><li class="half_rhythm"><div><b>VWF:CB.</b> Collagen-binding assays measure the ability of VWF to bind to specific collagens. A reduced VWF:CB-to-VWF:Ag ratio can be identified in individuals with type 2A, 2B, or 2M VWD. This assay is necessary to identify isolated VWF collagen-binding defects in some forms of type 2M VWD. Most clinical VWF:CB assays use a mixture of collagen type I and type III or collagen type III alone. Assays to assess for isolated deficient binding to collagen types IV and VI, as is found in some individuals with type 2M VWD, are available in specialty reference laboratories.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTclassificationofvwdb"><a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object" title="Table 1. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTclassificationofvwdb"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.classification_of_vwd_b"><a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclassificationofvwdb">Table 1. </a></h4><p class="float-caption no_bottom_margin">Classification of VWD Based on Specific Laboratory Tests </p></div></div><p><b>Molecular genetic testing</b> can be used to establish the diagnosis of VWD in a proband with ambiguous or conflicting quantitative and qualitative VWF testing and/or classify VWD subtype (see <a href="/books/NBK7014/table/von-willebrand.T.molecular_genetic_testi/?report=objectonly" target="object" rid-ob="figobvonwillebrandTmoleculargenetictesti">Table 2</a>).</p><ul><li class="half_rhythm"><div>Identification of a heterozygous (or, rarely, biallelic) VWD-causing variant in <i>VWF</i> can establish the diagnosis in individuals with <b>types 1C, 2A, 2B, and 2M VWD</b>. Note: The proportion of individuals with type 1 VWD who have a VWD-causing variant identified is lower than other forms of VWD; however, molecular genetic testing can still inform the diagnosis.</div></li><li class="half_rhythm"><div>Identification of biallelic VWD-causing variants in <i>VWF</i> can establish the diagnosis in individuals with <b>types 2N and 3 VWD</b>.</div></li></ul><p>Note: (1) Molecular genetic testing should be done in a laboratory experienced in testing for VWD. (2) Laboratories may not report the common benign <i>VWF</i> variant <a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvwfpathogenicvariants">p.Asp1472His</a>, which causes artificially decreased results on VWF:GPIbR and VWF:RCo assays.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-gene testing.</b> Sequence analysis of <i>VWF</i> is performed first to detect missense, nonsense, and splice site variants and small deletions/insertions. Depending on the sequencing method used, large deletions or duplications and <i>VWF-VWFP1</i> pseudogene conversions may not be detected (see <a href="#von-willebrand.Molecular_Genetics">Molecular Genetics</a>, <b><i>VWF</i>-specific laboratory technical considerations</b>). If no VWD-causing variant is detected by the sequencing method used in an individual with clinical and laboratory features of VWD, the next step is to perform testing that can identify large <i>VWF</i> deletions, duplications, and other structural variants.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A multigene panel</b> that includes <i>VWF</i>, <i>F8</i>, and <i>GPIBA</i> (see <a href="#von-willebrand.Differential_Diagnosis">Differential Diagnosis</a>) may be considered to identify the genetic cause of the condition and/or distinguish VWD from hemophilia A and PT-VWD. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. (5) Multigene panels usually cannot detect the common recurring <i>F8</i> intron 1 and intron 22 inversions.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTmoleculargenetictesti"><a href="/books/NBK7014/table/von-willebrand.T.molecular_genetic_testi/?report=objectonly" target="object" title="Table 2. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTmoleculargenetictesti"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.molecular_genetic_testi"><a href="/books/NBK7014/table/von-willebrand.T.molecular_genetic_testi/?report=objectonly" target="object" rid-ob="figobvonwillebrandTmoleculargenetictesti">Table 2. </a></h4><p class="float-caption no_bottom_margin">Molecular Genetic Testing Used in von Willebrand Disease </p></div></div></div></div><div id="von-willebrand.Clinical_Characteristics"><h2 id="_von-willebrand_Clinical_Characteristics_">Clinical Characteristics</h2><div id="von-willebrand.Clinical_Description"><h3>Clinical Description</h3><p>Von Willebrand disease (VWD) is a congenital bleeding disorder. Symptoms may only become apparent on hemostatic challenge, and increased or prolonged bleeding may only be identified after recurrent exposure to hemostatic challenges. Thus, it may take some time before a bleeding history becomes apparent. Individuals with VWD primarily manifest excessive mucocutaneous bleeding (e.g., bruising, epistaxis, ear, nose, and throat bleeding, oral bleeding, heavy menstrual bleeding) and do not tend to experience musculoskeletal bleeding in the absence of trauma unless the factor VIII clotting (FVIII:C) level is low, as can be seen in individuals with type 2N or type 3 VWD.</p><p><b>Type 1 VWD</b> typically manifests as mucocutaneous bleeding. However, the severity can range from mild to severe. Epistaxis and bruising are common. Heavy menstrual bleeding is the most common finding in females who menstruate [<a class="bibr" href="#von-willebrand.REF.ragni.2016.397" rid="von-willebrand.REF.ragni.2016.397">Ragni et al 2016</a>].</p><p><b>Type 1C VWD.</b> Individuals have accelerated clearance of VWF [<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al 2021</a>]. Bleeding occurs in the same pattern as in type 1 VWD, but symptoms tend to be milder compared to similarly low VWF levels in type 1 VWD.</p><p><b>Type 2A VWD.</b> Individuals with type 2A VWD can present with mild-to-severe mucocutaneous bleeding [<a class="bibr" href="#von-willebrand.REF.veyradier.2016.e3038" rid="von-willebrand.REF.veyradier.2016.e3038">Veyradier et al 2016</a>].</p><p><b>Type 2B VWD.</b> Individuals with type 2B VWD can present with mild-to-severe mucocutaneous bleeding. Thrombocytopenia may be present. A hallmark of type 2B VWD is a worsening of thrombocytopenia during stressful situations (e.g., severe infection, surgery, pregnancy) or in those treated with desmopressin [<a class="bibr" href="#von-willebrand.REF.federici.2009.526" rid="von-willebrand.REF.federici.2009.526">Federici et al 2009</a>].</p><p><b>Type 2M VWD.</b> Individuals with type 2M VWD can present with mild-to-severe mucocutaneous bleeding, including bleeding after surgeries and postpartum hemorrhage [<a class="bibr" href="#von-willebrand.REF.castaman.2012.632" rid="von-willebrand.REF.castaman.2012.632">Castaman et al 2012</a>, <a class="bibr" href="#von-willebrand.REF.larsen.2013.590" rid="von-willebrand.REF.larsen.2013.590">Larsen et al 2013</a>, <a class="bibr" href="#von-willebrand.REF.maas.2022.316" rid="von-willebrand.REF.maas.2022.316">Maas et al 2022</a>].</p><p><b>Type 2N VWD.</b> The clinical manifestations of type 2N VWD include joint, muscle, and mucocutaneous bleeding and excessive bleeding at the time of surgery or procedures [<a class="bibr" href="#von-willebrand.REF.van_meegeren.2015.e375" rid="von-willebrand.REF.van_meegeren.2015.e375">van Meegeren et al 2015</a>, <a class="bibr" href="#von-willebrand.REF.seidizadeh.2021.909" rid="von-willebrand.REF.seidizadeh.2021.909">Seidizadeh et al 2021</a>].</p><p><b>Type 3 VWD</b> manifests with moderate-to-severe bleeding including excessive mucocutaneous bleeding, musculoskeletal bleeding, and risk for intracranial hemorrhage [<a class="bibr" href="#von-willebrand.REF.metjian.2009.918" rid="von-willebrand.REF.metjian.2009.918">Metjian et al 2009</a>, <a class="bibr" href="#von-willebrand.REF.ahmad.2013.652" rid="von-willebrand.REF.ahmad.2013.652">Ahmad et al 2013</a>, <a class="bibr" href="#von-willebrand.REF.kasatkar.2014.e92575" rid="von-willebrand.REF.kasatkar.2014.e92575">Kasatkar et al 2014</a>, <a class="bibr" href="#von-willebrand.REF.tosetto.2020.2145" rid="von-willebrand.REF.tosetto.2020.2145">Tosetto et al 2020</a>].</p><p>
|
|
<b>Associated complications</b>
|
|
</p><ul><li class="half_rhythm"><div><b>Gastrointestinal (GI) angiodysplasia</b> occurs in all types of VWD, most commonly in adults with type 2A VWD, followed by type 3 and type 1 VWD [<a class="bibr" href="#von-willebrand.REF.chornenki.2022.624" rid="von-willebrand.REF.chornenki.2022.624">Chornenki et al 2022</a>]. It occurs throughout the GI tract, particularly the colon, small intestine, and stomach [<a class="bibr" href="#von-willebrand.REF.franchini.2014.427" rid="von-willebrand.REF.franchini.2014.427">Franchini & Mannucci 2014</a>]. GI angiodysplasia presents with GI bleeding that may begin insidiously, sometimes only recognizable through identification of iron deficiency or anemia or on endoscopy. As angiodysplasia progresses, GI bleeding generally worsens, and bleeding episodes may become life-threatening.</div></li><li class="half_rhythm"><div><b>Alloantibodies against VWF.</b> The development of alloantibodies against VWF (anti-VWF antibodies) is an uncommon but serious complication of VWD treatment. An estimated 5%-10% of individuals with type 3 VWD develop anti-VWF antibodies, although these antibodies are exceedingly rare in other VWD types [<a class="bibr" href="#von-willebrand.REF.franchini.2018.590" rid="von-willebrand.REF.franchini.2018.590">Franchini & Mannucci 2018</a>]. Affected individuals present with reduced or absent response to treatment with VWF replacement or, in rare instances, with anaphylactic reaction. Individuals with large <i>VWF</i> deletions and those who have had multiple episodes of VWF replacement (i.e., multiple exposure days) are at highest risk for this complication.</div></li></ul></div><div id="von-willebrand.GenotypePhenotype_Correla"><h3>Genotype-Phenotype Correlations</h3><p>The three phenotypes reflect a partial quantitative deficiency of VWF (type 1 VWD), complete quantitative deficiency of VWF (type 3 VWD), or qualitative defects in VWF (type 2 VWD). See <a href="#von-willebrand.Molecular_Genetics">Molecular Genetics</a> for details regarding the genotypes associated with each subtype of VWD.</p><p>Individuals with large deletions of <i>VWF</i> are at highest risk for alloantibody development, although null alleles have also been associated with this complication [<a class="bibr" href="#von-willebrand.REF.franchini.2018.590" rid="von-willebrand.REF.franchini.2018.590">Franchini & Mannucci 2018</a>].</p></div><div id="von-willebrand.Penetrance"><h3>Penetrance</h3><p><b>Type 1 VWD (autosomal dominant).</b> VWD-causing variants resulting in plasma VWF levels lower than 30 IU/dL tend to be more penetrant.</p><p><b>Other autosomal dominant types (2A, 2B, and 2M).</b> VWD-causing variants are often fully penetrant, particularly for type 2A and type 2B VWD.</p></div><div id="von-willebrand.Nomenclature"><h3>Nomenclature</h3><p>Clarifications and changes in VWD nomenclature are listed in <a href="/books/NBK7014/table/von-willebrand.T.clarifications_and_chan/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclarificationsandchan">Table 3</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTclarificationsandchan"><a href="/books/NBK7014/table/von-willebrand.T.clarifications_and_chan/?report=objectonly" target="object" title="Table 3. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTclarificationsandchan"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.clarifications_and_chan"><a href="/books/NBK7014/table/von-willebrand.T.clarifications_and_chan/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclarificationsandchan">Table 3. </a></h4><p class="float-caption no_bottom_margin">Clarifications and Changes in von Willebrand Disease Nomenclature </p></div></div><p><b>Platelet-type von Willebrand disease (PT-VWD)</b>, previously called pseudo-VWD, is a platelet disorder caused by pathogenic variants in <i>GP1BA</i> and, thus, is not a form of VWD (see <a href="#von-willebrand.Differential_Diagnosis">Differential Diagnosis</a>) [<a class="bibr" href="#von-willebrand.REF.fu.2024" rid="von-willebrand.REF.fu.2024">Fu et al 2024</a>].</p><p><b>Acquired von Willebrand syndrome (AVWS),</b> previously known as acquired VWD, is the preferred terminology for defects in VWF concentration, structure, or function that are neither inherited nor due to disease-causing variants in <i>VWF</i>, and instead arise as consequences of other medical conditions (see <a href="#von-willebrand.Differential_Diagnosis">Differential Diagnosis</a>) [<a class="bibr" href="#von-willebrand.REF.franchini.2020.2032" rid="von-willebrand.REF.franchini.2020.2032">Franchini & Mannucci 2020</a>].</p></div><div id="von-willebrand.Prevalence"><h3>Prevalence</h3><p>VWD affects 0.1% of the population. Prior estimates that VWD affects up to 1% of the population likely included people with low VWF without excessive bleeding. One in 10,000 individuals seek tertiary care referral for VWD.</p><p>Type 3 VWD affects 0.5:1,000,000 to 6:1,000,000.</p><p>Founder variants in <i>VWF</i> that account for a significant proportion of disease-causing variants in a specific population have been reported in the Romani and Amish populations (see <a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvwfpathogenicvariants">Table 9</a>).</p></div></div><div id="von-willebrand.Genetically_Related_Allel"><h2 id="_von-willebrand_Genetically_Related_Allel_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with germline pathogenic variants in <i>VWF</i>.</p></div><div id="von-willebrand.Differential_Diagnosis"><h2 id="_von-willebrand_Differential_Diagnosis_">Differential Diagnosis</h2><p>Mild-to-moderate hemophilia A and platelet-type von Willebrand disease (PT-VWD) can be difficult to distinguish phenotypically from von Willebrand disease (VWD) (see <a href="/books/NBK7014/table/von-willebrand.T.genetic_disorders_in_th/?report=objectonly" target="object" rid-ob="figobvonwillebrandTgeneticdisordersinth">Table 4</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTgeneticdisordersinth"><a href="/books/NBK7014/table/von-willebrand.T.genetic_disorders_in_th/?report=objectonly" target="object" title="Table 4. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTgeneticdisordersinth"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.genetic_disorders_in_th"><a href="/books/NBK7014/table/von-willebrand.T.genetic_disorders_in_th/?report=objectonly" target="object" rid-ob="figobvonwillebrandTgeneticdisordersinth">Table 4. </a></h4><p class="float-caption no_bottom_margin">Genetic Disorders in the Differential Diagnosis of von Willebrand Disease </p></div></div><p><b>Acquired von Willebrand syndrome (AVWS)</b> is a bleeding disorder of qualitative or quantitative deficiency of von Willebrand factor (VWF) that can occur in a variety of conditions and is neither inherited nor due to disease-causing variants in <i>VWF</i> [<a class="bibr" href="#von-willebrand.REF.sucker.2009.177" rid="von-willebrand.REF.sucker.2009.177">Sucker et al 2009</a>, <a class="bibr" href="#von-willebrand.REF.federici.2013.191" rid="von-willebrand.REF.federici.2013.191">Federici et al 2013</a>, <a class="bibr" href="#von-willebrand.REF.mital.2016.1337" rid="von-willebrand.REF.mital.2016.1337">Mital 2016</a>, <a class="bibr" href="#von-willebrand.REF.franchini.2020.2032" rid="von-willebrand.REF.franchini.2020.2032">Franchini & Mannucci 2020</a>]. AVWS is most often seen in persons older than age 40 years with no prior bleeding history. AVWS has diverse pathology and causes including the following:</p><ul><li class="half_rhythm"><div>Lymphoproliferative or plasma cell proliferative disorders, paraproteinemias (monoclonal gammopathy of unknown significance), chronic lymphocytic leukemia, multiple myeloma, and Waldenstrom macroglobulinemia. Antibodies against VWF have been detected in some individuals with these disorders.</div></li><li class="half_rhythm"><div>Autoimmune disorders including systemic lupus erythematosus, scleroderma, and antiphospholipid antibody syndrome</div></li><li class="half_rhythm"><div>Shear-induced VWF conformational changes leading to relative loss of high-molecular-weight VWF multimers (e.g., aortic valve stenosis, ventricular septal defect, left ventricular assist devices)</div></li><li class="half_rhythm"><div>Markedly increased blood platelet count (e.g., essential thrombocythemia or other myeloproliferative disorders)</div></li><li class="half_rhythm"><div>Removal of VWF from circulation by aberrant binding to tumor cells (e.g., Wilms tumor or certain lymphoproliferative disorders) or amyloidosis</div></li><li class="half_rhythm"><div>Decreased VWF synthesis (e.g., hypothyroidism)</div></li><li class="half_rhythm"><div>Certain drugs (e.g., valproic acid, ciprofloxacin, griseofulvin, hydroxyethyl starch, N-acetylcysteine)</div></li></ul></div><div id="von-willebrand.Management"><h2 id="_von-willebrand_Management_">Management</h2><p>Clinical practice guidelines for von Willebrand disease (VWD) have been published [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>].</p><div id="von-willebrand.Evaluations_Following_Ini"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with VWD, the evaluations summarized in <a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_1/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease1">Table 5</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTvonwillebranddisease1"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_1/?report=objectonly" target="object" title="Table 5. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTvonwillebranddisease1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.von_willebrand_disease_1"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_1/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease1">Table 5. </a></h4><p class="float-caption no_bottom_margin">Von Willebrand Disease: Recommended Evaluations Following Initial Diagnosis </p></div></div></div><div id="von-willebrand.Treatment_of_Manifestatio"><h3>Treatment of Manifestations</h3><div id="von-willebrand.Targeted_Therapy"><h4>Targeted Therapy</h4><p>
|
|
<i>In GeneReviews, a targeted therapy is one that addresses the specific underlying mechanism of disease causation (regardless of whether the therapy is significantly efficacious for one or more manifestation of the genetic condition); would otherwise not be considered without knowledge of the underlying genetic cause of the condition; or could lead to a cure</i>. —ED</p><p>Von Willebrand factor (VWF) factor replacement (plasma derived or recombinant) is the mainstay of VWD treatment. Desmopressin can be used in individuals who are responsive to desmopressin for non-major, time-limited hemostatic challenges. Guidance on the treatment of VWD has been published [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>].</p><p>
|
|
<b>Intravenous infusion of VWF replacement</b>
|
|
</p><ul><li class="half_rhythm"><div>VWF replacement options include pathogen-inactivated plasma-derived products containing both VWF and factor VIII (FVIII), plasma-derived products depleted of FVIII, and recombinant VWF that does not provide FVIII [<a class="bibr" href="#von-willebrand.REF.weyand.2021.1085" rid="von-willebrand.REF.weyand.2021.1085">Weyand & Flood 2021</a>].</div></li><li class="half_rhythm"><div>Bleeding episodes can be prevented or controlled with intravenous infusion of VWF-containing replacement treatments.</div></li><li class="half_rhythm"><div>Plasma-derived concentrates are prepared from pooled blood donations from many donors. Procedures such as pasteurization and detergents inactivate potential pathogens.</div></li><li class="half_rhythm"><div>Recombinant VWF is manufactured in vitro [<a class="bibr" href="#von-willebrand.REF.franchini.2016.825" rid="von-willebrand.REF.franchini.2016.825">Franchini & Mannucci 2016</a>].</div></li></ul><p>
|
|
<b>Desmopressin</b>
|
|
</p><ul><li class="half_rhythm"><div>Many individuals with type 1 VWD respond to intranasal, intravenous, or subcutaneous treatment with desmopressin [<a class="bibr" href="#von-willebrand.REF.leissinger.2014.158" rid="von-willebrand.REF.leissinger.2014.158">Leissinger et al 2014</a>]. Desmopressin promotes release of stored VWF and raises VWF and FVIII levels three- to fourfold.</div></li><li class="half_rhythm"><div>Following the diagnosis of type 1 VWD, a desmopressin challenge is recommended to assess VWF response [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>]. Desmopressin challenges are no longer recommended routinely in individuals with other types of VWD, although it may be occasionally useful in some individuals with type 2 VWD.</div></li><li class="half_rhythm"><div>Individuals with type 1C VWD will have accelerated VWF clearance after diagnostic desmopressin challenge [<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al 2021</a>]. Desmopressin is generally contraindicated in type 1C VWD for surgery [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>].</div></li><li class="half_rhythm"><div>Desmopressin should be used with caution, particularly in those younger than age two years, because of the potential difficulty in restricting fluids in this age group.</div></li><li class="half_rhythm"><div>Repeat dosing of desmopressin over a short period of time results in tachyphylaxis: a decrease of released VWF after repeated administration.</div></li><li class="half_rhythm"><div>Desmopressin is contraindicated in individuals with arteriovascular disease and in those older than age 70 years.</div></li><li class="half_rhythm"><div>In persons who do not tolerate desmopressin, who have a poor VWF response, who face a moderate or major hemostatic challenge, who cannot sufficiently fluid restrict, or who have a duration of hemostatic need longer than a few days, VWF replacement treatment is required.</div></li><li class="half_rhythm"><div>Note: Because desmopressin can cause hyponatremia through the retention of free water (which can lead to seizures, coma, or death), fluid intake should be restricted for 24 hours following its administration to minimize this risk.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTtargetedtherapybyvon"><a href="/books/NBK7014/table/von-willebrand.T.targeted_therapy_by_von/?report=objectonly" target="object" title="Table 6. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTtargetedtherapybyvon"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.targeted_therapy_by_von"><a href="/books/NBK7014/table/von-willebrand.T.targeted_therapy_by_von/?report=objectonly" target="object" rid-ob="figobvonwillebrandTtargetedtherapybyvon">Table 6. </a></h4><p class="float-caption no_bottom_margin">Targeted Therapy by von Willebrand Disease Type </p></div></div></div><div id="von-willebrand.Supportive_Care"><h4>Supportive Care</h4><p>Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This ideally involves multidisciplinary care by a comprehensive bleeding disorders program (see <a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_2/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease2">Table 7</a>). The goal is to develop treatment plans that enable people with VWD to live full and active lives.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTvonwillebranddisease2"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_2/?report=objectonly" target="object" title="Table 7. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTvonwillebranddisease2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.von_willebrand_disease_2"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_2/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease2">Table 7. </a></h4><p class="float-caption no_bottom_margin">Von Willebrand Disease: Treatment of Manifestations </p></div></div></div></div><div id="von-willebrand.Surveillance"><h3>Surveillance</h3><p>To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in <a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_3/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease3">Table 8</a> are recommended.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTvonwillebranddisease3"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_3/?report=objectonly" target="object" title="Table 8. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTvonwillebranddisease3"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.von_willebrand_disease_3"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_3/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvonwillebranddisease3">Table 8. </a></h4><p class="float-caption no_bottom_margin">Von Willebrand Disease: Recommended Surveillance </p></div></div></div><div id="von-willebrand.AgentsCircumstances_to_Av"><h3>Agents/Circumstances to Avoid</h3><p>Activities with a high risk of trauma should be approached with caution and full protective gear should be used in sports and recreational activities; high contact sports with risk of head injury should be avoided.</p><p>Medications that affect platelet function (e.g., aspirin, clopidogrel) should only be used for clear medical indications and with counseling and monitoring for bleeding, as these medications can worsen bleeding symptoms.</p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase bleeding risk and should be used cautiously and only for brief periods.</p><p>Nutritional supplements that may impair hemostasis (e.g., fish oil, turmeric) should be avoided.</p><p>All invasive procedures require prior consultation with a hematologist regardless of how minor they are perceived to be by the proceduralist, including common outpatient medical procedures (e.g., circumcision, dental, dermatologic) and non-medical procedures (e.g., piercings).</p></div><div id="von-willebrand.Evaluation_of_Relatives_a"><h3>Evaluation of Relatives at Risk</h3><p><b>Newborn at risk for VWD.</b> The mother should be counseled during pregnancy regarding the increased risk for bleeding complications (see <a href="#von-willebrand.Pregnancy_Management">Pregnancy Management</a>) and a high-risk obstetrician, neonatologist, and pediatric hematologist should be notified of the risk of VWD in the infant before birth. Evaluation of newborns at risk for VWD can include:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>VWD laboratory assays.</b> For newborns at-risk for more severe forms of type 1, type 2, or type 3 VWD, cord blood should be obtained to assess for low VWF and FVIII levels to inform neonatal treatment. Assess platelet count on cord blood to evaluate newborns at risk for type 2B VWD. The stress of birth, sample handling, and the immature neonatal hemostasis system can all affect clotting factor levels in cord blood.</div><div class="half_rhythm">In newborns with early life complications and anticipated hemostatic challenges (e.g., invasive procedures and/or NICU hospitalization), it is important to assess VWF and FVIII levels as early as possible. More definitive VWD testing (see <a href="#von-willebrand.Establishing_the_Diagnosi">Establishing the Diagnosis</a>) should be done at an older age to confirm cord blood findings or for diagnosis in otherwise healthy infants without anticipated hemostatic challenges.</div></li><li class="half_rhythm"><div class="half_rhythm"><b><i>VWF</i> molecular genetic testing of cord blood</b>. Molecular genetic testing is most informative when the familial <i>VWF</i> variant(s) are known. (If the familial VWD<i>-</i>causing variant[s] are not known, the absence of an identified VWD<i>-</i>causing variant in a cord blood sample cannot be used to rule out the possibility of VWD.)</div></li></ul><p><b>Other at-risk relatives.</b> It is appropriate to evaluate even apparently asymptomatic at-risk relatives of an affected individual to allow early diagnosis and treatment as needed [<a class="bibr" href="#von-willebrand.REF.goodeve.2016.678" rid="von-willebrand.REF.goodeve.2016.678">Goodeve 2016</a>]. Evaluations can include:</p><ul><li class="half_rhythm"><div>VWD hemostasis factor assays sensitive and specific for VWD (see <a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object" rid-ob="figobvonwillebrandTclassificationofvwdb">Table 1</a>) regardless of if the type of VWD and/or VWD-causing variant(s) in the family are known;</div></li><li class="half_rhythm"><div>Molecular genetic testing if the VWD-causing variant(s) in the family are known.</div></li></ul><p>See <a href="#von-willebrand.Related_Genetic_Counselin">Genetic Counseling</a> for issues related to testing of at-risk relatives for genetic counseling purposes.</p></div><div id="von-willebrand.Pregnancy_Management"><h3>Pregnancy Management</h3><p>VWF levels increase throughout pregnancy, with the peak occurring four hours after delivery [<a class="bibr" href="#von-willebrand.REF.james.2015.81" rid="von-willebrand.REF.james.2015.81">James et al 2015</a>, <a class="bibr" href="#von-willebrand.REF.johnsen.2022.1568" rid="von-willebrand.REF.johnsen.2022.1568">Johnsen & MacKinnon 2022</a>]. Nonetheless, pregnant people with VWD are at increased risk for bleeding complications, and care should be provided in centers with experience in perinatal management of bleeding disorders [<a class="bibr" href="#von-willebrand.REF.johnsen.2022.1568" rid="von-willebrand.REF.johnsen.2022.1568">Johnsen & MacKinnon 2022</a>].</p><p>The 2021 VWD guidelines do not address target VWF levels for delivery [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>]. Some providers will treat to keep VWF levels >100 IU/dL for delivery, while nearly all providers agree that a VWF level <50 IU/dL should be increased prior to delivery [<a class="bibr" href="#von-willebrand.REF.punt.2020.100633" rid="von-willebrand.REF.punt.2020.100633">Punt et al 2020</a>, <a class="bibr" href="#von-willebrand.REF.johnsen.2022.1568" rid="von-willebrand.REF.johnsen.2022.1568">Johnsen & MacKinnon 2022</a>, <a class="bibr" href="#von-willebrand.REF.lavin.2022.82" rid="von-willebrand.REF.lavin.2022.82">Lavin et al 2022</a>, <a class="bibr" href="#von-willebrand.REF.lim.2024.470" rid="von-willebrand.REF.lim.2024.470">Lim et al 2024</a>]. VWD 2021 guidelines suggest a target VWF level of ≥50 IU/dL for those undergoing neuraxial anesthesia [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>].</p><p>Although deliveries should occur based on obstetric indications, use of instrumentation to assist delivery (e.g., forceps, vacuum) should be minimized whenever possible [<a class="bibr" href="#von-willebrand.REF.johnsen.2022.1568" rid="von-willebrand.REF.johnsen.2022.1568">Johnsen & MacKinnon 2022</a>]. Episiotomies should be avoided whenever possible. Fetal scalp electrodes and scalp blood sampling should be avoided in individuals with most forms of VWD due to the risk that the fetus has VWD.</p><p>Delayed, secondary postpartum bleeding rates are high in individuals with VWD. VWD 2021 guidelines suggest the use of tranexamic acid for postpartum hemorrhage prophylaxis. The guidelines do not address duration of postpartum treatment [<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al 2021</a>]. VWF level rapidly returns to pre-pregnancy levels following delivery [<a class="bibr" href="#von-willebrand.REF.james.2015.81" rid="von-willebrand.REF.james.2015.81">James et al 2015</a>].</p></div><div id="von-willebrand.Therapies_Under_Investiga"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not always be clinical trials for this disorder.</p></div></div><div id="von-willebrand.Genetic_Counseling"><h2 id="_von-willebrand_Genetic_Counseling_">Genetic Counseling</h2><p>
|
|
<i>Genetic counseling is the process of providing individuals and families with
|
|
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
|
|
make informed medical and personal decisions. The following section deals with genetic
|
|
risk assessment and the use of family history and genetic testing to clarify genetic
|
|
status for family members; it is not meant to address all personal, cultural, or
|
|
ethical issues that may arise or to substitute for consultation with a genetics
|
|
professional</i>. —ED.</p><div id="von-willebrand.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Type 1, type 2A, and type 2M von Willebrand disease (VWD) are typically caused by a heterozygous <i>VWF</i> variant and inherited in an autosomal dominant manner; rarely, these VWD types are associated with biallelic <i>VWF</i> variants.</p><p>Type 2B VWD is typically caused by a heterozygous <i>VWF</i> variant and inherited in an autosomal dominant manner.</p><p>Type 2N and type 3 VWD are caused by biallelic <i>VWF</i> variants and inherited in an autosomal recessive manner.</p></div><div id="von-willebrand.Autosomal_Dominant_Inheri"><h3>Autosomal Dominant Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>Many individuals diagnosed with autosomal dominant VWD have an affected parent.</div></li><li class="half_rhythm"><div>A proband with autosomal dominant VWD may have the disorder as the result of a <i>de novo</i> VWD-causing variant. <i>De novo</i> VWD-causing variants have been reported rarely in type 1 VWD [<a class="bibr" href="#von-willebrand.REF.james.2007a.145" rid="von-willebrand.REF.james.2007a.145">James et al 2007a</a>, <a class="bibr" href="#von-willebrand.REF.ahmad.2014.e311" rid="von-willebrand.REF.ahmad.2014.e311">Ahmad et al 2014</a>] and type 2 VWD [<a class="bibr" href="#von-willebrand.REF.shen.2016.36" rid="von-willebrand.REF.shen.2016.36">Shen et al 2016</a>, <a class="bibr" href="#von-willebrand.REF.chen.2022.5403" rid="von-willebrand.REF.chen.2022.5403">Chen et al 2022</a>].</div></li><li class="half_rhythm"><div>If the proband appears to be the only affected family member (i.e., a simplex case), hemostasis laboratory assays and (if a molecular diagnosis has been established in the proband) <i>VWF</i> molecular genetic testing are recommended for the parents of the proband to confirm their status, allow reliable recurrence counseling, and determine their need for VWD treatment.</div></li><li class="half_rhythm"><div>If the VWD-causing variant identified in the proband is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>The proband has a <i>de novo</i> VWD-causing variant.</div></li><li class="half_rhythm"><div>The proband inherited a VWD-causing variant from a parent with gonadal (or somatic and gonadal) mosaicism. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a VWD-causing variant that is present in the germ (gonadal) cells only.</div></li></ul></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with autosomal dominant VWD may appear to be negative because of failure to recognize the disorder in family members, reduced penetrance, variable expressivity, early death of an informative relative (such as a parent) before the recognition of symptoms, or delay of significant hemostatic challenges in affected relatives. Therefore, an apparently negative family history cannot be confirmed without appropriate evaluations (e.g., VWD laboratory assays) and/or molecular genetic testing (to establish that neither parent has VWD-causing variant[s]).</div></li></ul><p><b>Sibs of a proband.</b> The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the proband is affected and/or is known to have the VWD-causing variant identified in the proband, the risk to the sibs is 50%. VWD often exhibits variable penetrance and expressivity, meaning that not all sibs who inherit a <i>VWF</i> variant will have symptoms of VWD, and that those who have VWD-related manifestations can bleed with variable severity.</div></li><li class="half_rhythm"><div>If the proband has a known VWD-causing variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental gonadal mosaicism [<a class="bibr" href="#von-willebrand.REF.chen.2022.5403" rid="von-willebrand.REF.chen.2022.5403">Chen et al 2022</a>].</div></li><li class="half_rhythm"><div>If the parents are clinically unaffected but their genetic status is unknown, the risk to the sibs of a proband is increased over that of the general population because of the possibility of reduced penetrance in a heterozygous parent (see <a href="#von-willebrand.Penetrance">Penetrance</a>) or parental gonadal mosaicism.</div></li></ul><p>
|
|
<b>Offspring of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>Each child of an individual with autosomal dominant VWD has a 50% chance of inheriting the VWD-causing variant.</div></li><li class="half_rhythm"><div>If the proband's reproductive partner also has VWD-causing variant(s), offspring are at risk of inheriting biallelic VWD<i>-</i>causing variants and potentially having a more severe phenotype or different VWD type than the proband.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the proband's parents: if a parent is affected, the parent's family members may be at risk.</p></div><div id="von-willebrand.Autosomal_Recessive_Inher"><h3>Autosomal Recessive Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>The parents of an individual with autosomal recessive VWD are typically heterozygous for one VWD-causing variant. Alternatively, it is possible that one or both parents have biallelic VWD-causing variants.</div></li><li class="half_rhythm"><div>If a molecular diagnosis has been established in the proband, molecular genetic testing is recommended for the parents of the proband to confirm their genetic status and allow reliable recurrence risk assessment. If a VWD-causing variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>One of the VWD-causing variants identified in the proband occurred as a <i>de novo</i> event in the proband or as a postzygotic <i>de novo</i> event in a mosaic parent [<a class="bibr" href="#von-willebrand.REF.j_nsson.2017.519" rid="von-willebrand.REF.j_nsson.2017.519">Jónsson et al 2017</a>].</div></li><li class="half_rhythm"><div>Uniparental isodisomy for the parental chromosome with the VWD-causing variant resulted in homozygosity for the VWD-causing variant in the proband. Maternal uniparental isodisomy has been reported in type 3 VWD [<a class="bibr" href="#von-willebrand.REF.boisseau.2011.1567" rid="von-willebrand.REF.boisseau.2011.1567">Boisseau et al 2011</a>].</div></li></ul></li><li class="half_rhythm"><div>Heterozygous parents of an individual with type 2N VWD are often asymptomatic. However, a small proportion of these heterozygous individuals may show some mild bleeding symptoms and lower factor VIII (FVIII) levels and may be diagnosed with VWD.</div></li><li class="half_rhythm"><div>Heterozygous parents of an individual with type 3 VWD can have normal VWF levels and be asymptomatic. However, between 15% and 50% may show some mild bleeding symptoms and may be diagnosed with type 1 VWD [<a class="bibr" href="#von-willebrand.REF.nichols.2008.171" rid="von-willebrand.REF.nichols.2008.171">Nichols et al 2008</a>, <a class="bibr" href="#von-willebrand.REF.bowman.2013.512" rid="von-willebrand.REF.bowman.2013.512">Bowman et al 2013</a>, <a class="bibr" href="#von-willebrand.REF.christopherson.2022.1576" rid="von-willebrand.REF.christopherson.2022.1576">Christopherson et al 2022</a>].</div></li></ul><p>
|
|
<b>Sibs of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>If both parents are known to be heterozygous for a VWD-causing variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial VWD-causing variants.</div></li><li class="half_rhythm"><div>Heterozygous sibs of an individual with type 2N VWD are often asymptomatic. However, a small proportion of these heterozygous individuals may show some mild bleeding symptoms and lower FVIII levels and may be diagnosed with VWD.</div></li><li class="half_rhythm"><div>Heterozygous sibs of an individual with type 3 VWD can have normal VWF levels and be asymptomatic. However, between 15% and 50% may have some bleeding symptoms and low VWF levels and be diagnosed with type 1 VWD [<a class="bibr" href="#von-willebrand.REF.nichols.2008.171" rid="von-willebrand.REF.nichols.2008.171">Nichols et al 2008</a>, <a class="bibr" href="#von-willebrand.REF.bowman.2013.512" rid="von-willebrand.REF.bowman.2013.512">Bowman et al 2013</a>, <a class="bibr" href="#von-willebrand.REF.christopherson.2022.1576" rid="von-willebrand.REF.christopherson.2022.1576">Christopherson et al 2022</a>].</div></li></ul><p><b>Offspring of a proband.</b> Unless an affected individual's reproductive partner also has a VWD-causing variant(s), offspring will be obligate heterozygotes for a VWD-causing variant.</p><p><b>Other family members.</b> Each sib of the proband's parents is at a 50% risk of being heterozygous for a VWD-causing variant.</p><p><b>Heterozygote detection.</b> Molecular genetic heterozygote testing for at-risk relatives is most informative if the VWD-causing variants have been identified in an affected family member.</p></div><div id="von-willebrand.Related_Genetic_Counselin"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#von-willebrand.Evaluation_of_Relatives_a">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>
|
|
<b>Family planning</b>
|
|
</p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who have VWD-causing variant(s).</div></li><li class="half_rhythm"><div>Genetic testing should be considered for the reproductive partners of individuals with VWD-causing variant(s), particularly if consanguinity is likely and/or if both partners have the same ancestral background. <i>VWF</i> founder variants have been identified in individuals of Romani heritage and in the Amish population (see <a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvwfpathogenicvariants">Table 9</a>).</div></li></ul><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to retaining DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown) or if the genetic findings incompletely explain the VWD phenotype. For more information, see <a class="bibr" href="#von-willebrand.REF.huang.2022.389" rid="von-willebrand.REF.huang.2022.389">Huang et al [2022]</a>.</p></div><div id="von-willebrand.Prenatal_Testing_and_Prei"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the VWD-causing variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing for VWD are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal and preimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.</p></div></div><div id="von-willebrand.Resources"><h2 id="_von-willebrand_Resources_">Resources</h2><p>
|
|
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
|
|
support organizations and/or registries for the benefit of individuals with this disorder
|
|
and their families. GeneReviews is not responsible for the information provided by other
|
|
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/?report=reader">here</a>.</i></p>
|
|
<ul><li class="half_rhythm"><div>
|
|
<b>Centers for Disease Control and Prevention</b>
|
|
</div><div>
|
|
<a href="https://www.cdc.gov/ncbddd/vwd/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Von Willebrand Disease</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>MedlinePlus</b>
|
|
</div><div>
|
|
<a href="https://medlineplus.gov/genetics/condition/von-willebrand-disease/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Von Willebrand disease</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>National Bleeding Disorders Foundation</b>
|
|
</div><div><b>Phone:</b> 888-463-6643</div><div><b>Email:</b> info@hemophilia.org</div><div>
|
|
<a href="https://www.hemophilia.org/bleeding-disorders-a-z/types/von-willebrand-disease" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">von Willebrand disease</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Canadian Hemophilia Society</b>
|
|
</div><div>Canada</div><div><b>Phone:</b> 800-668-2686</div><div><b>Email:</b> chs@hemophilia.ca</div><div>
|
|
<a href="https://www.hemophilia.ca" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">hemophilia.ca</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>The Haemophilia Society</b>
|
|
</div><div>United Kingdom</div><div><b>Phone:</b> 020 7939 0780</div><div><b>Email:</b> info@haemophilia.org.uk</div><div>
|
|
<a href="http://www.haemophilia.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">haemophilia.org.uk</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>World Federation of Hemophilia</b>
|
|
</div><div>Canada</div><div><b>Phone:</b> 514-875-7944</div><div><b>Fax:</b> 514-875-8916</div><div><b>Email:</b> wfh@wfh.org</div><div>
|
|
<a href="http://www.wfh.org" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">wfh.org</a>
|
|
</div></li></ul>
|
|
</div><div id="von-willebrand.Molecular_Genetics"><h2 id="_von-willebrand_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —</i>ED.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandmolgenTA"><a href="/books/NBK7014/table/von-willebrand.molgen.TA/?report=objectonly" target="object" title="Table A." class="img_link icnblk_img" rid-ob="figobvonwillebrandmolgenTA"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.molgen.TA"><a href="/books/NBK7014/table/von-willebrand.molgen.TA/?report=objectonly" target="object" rid-ob="figobvonwillebrandmolgenTA">Table A.</a></h4><p class="float-caption no_bottom_margin">Von Willebrand Disease: Genes and Databases </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandmolgenTB"><a href="/books/NBK7014/table/von-willebrand.molgen.TB/?report=objectonly" target="object" title="Table B." class="img_link icnblk_img" rid-ob="figobvonwillebrandmolgenTB"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.molgen.TB"><a href="/books/NBK7014/table/von-willebrand.molgen.TB/?report=objectonly" target="object" rid-ob="figobvonwillebrandmolgenTB">Table B.</a></h4><p class="float-caption no_bottom_margin">OMIM Entries for Von Willebrand Disease (View All in OMIM) </p></div></div><div id="von-willebrand.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The von Willebrand facto (VWF) protein is comprised of a 22-amino acid signal peptide, a 741-amino acid propeptide, and a 2,050-amino acid mature protein (see <a class="figpopup" href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" rid-figpopup="figvonwillebrandF3" rid-ob="figobvonwillebrandF3">Figure 3</a>). VWF has two key functions:</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figvonwillebrandF3" co-legend-rid="figlgndvonwillebrandF3"><a href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figvonwillebrandF3" rid-ob="figobvonwillebrandF3"><img class="small-thumb" src="/books/NBK7014/bin/von-willebrand-Image003.gif" src-large="/books/NBK7014/bin/von-willebrand-Image003.jpg" alt="Figure 3. . VWF protein structure and location of VWD-causing VWF variants by VWD type." /></a><div class="icnblk_cntnt" id="figlgndvonwillebrandF3"><h4 id="von-willebrand.F3"><a href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" rid-ob="figobvonwillebrandF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">VWF protein structure and location of VWD-causing VWF variants by VWD type. Bold horizontal lines indicate the approximate position of exons where VWD-causing variants are most prevalent; thinner lines indicate exons with variants of lower frequency. <a href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" rid-ob="figobvonwillebrandF3">(more...)</a></p></div></div><ul><li class="half_rhythm"><div>Binding to the subendothelium at sites of vascular damage and recruiting platelets to sites of clotting; and</div></li><li class="half_rhythm"><div>Protecting factor VIII (FVIII) from proteolytic degradation in circulation and transporting it to sites of clot generation.</div></li></ul><p>VWF has two sites of synthesis: endothelial cells and megakaryocytes, the precursors of platelets. During synthesis, tail-to-tail disulfide-linked dimers are formed through the C-terminal cystine knot (CK) domains, followed by head-to-head disulfide-linked VWF oligomers of up to 40 dimers in length.</p><p>During intracellular processing, the VWF propeptide (VWFpp) is cleaved by furin in the Golgi, plays a critical role in VWF multimerization, remains non-covalently associated with VWF through intracellular trafficking and storage, and is secreted into the plasma along with VWF [<a class="bibr" href="#von-willebrand.REF.haberichter.2015.1753" rid="von-willebrand.REF.haberichter.2015.1753">Haberichter 2015</a>]. The ratio of VWFpp to mature VWF (von Willebrand factor antigen or VWF:Ag) can be used to estimate relative half-life of mature VWF [<a class="bibr" href="#von-willebrand.REF.haberichter.2008.4979" rid="von-willebrand.REF.haberichter.2008.4979">Haberichter et al 2008</a>] and provide information about the mechanism of pathogenicity [<a class="bibr" href="#von-willebrand.REF.eikenboom.2013.2336" rid="von-willebrand.REF.eikenboom.2013.2336">Eikenboom et al 2013</a>]. The VWFpp-to-VWF:Ag ratio correlates poorly with rapid VWF clearance in individuals with VWF levels of 30-50 IU/dL [<a class="bibr" href="#von-willebrand.REF.doherty.2023.302" rid="von-willebrand.REF.doherty.2023.302">Doherty et al 2023</a>].</p><p>In circulation, high-molecular-wight VWF is cleaved to smaller VWF multimer forms by ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif) between amino acids 1605 and 1606 following secretion. The pattern of multimer proteolysis products by agarose-SDS gel analysis can help inform the underlying mechanism [<a class="bibr" href="#von-willebrand.REF.saadalla.2023.580" rid="von-willebrand.REF.saadalla.2023.580">Saadalla et al 2023</a>].</p><p><b>Type 1 von Willebrand disease (VWD).</b> Partial quantitative deficiency in type 1 VWD is mostly associated with missense variants [<a class="bibr" href="#von-willebrand.REF.seidizadeh.2024.2115" rid="von-willebrand.REF.seidizadeh.2024.2115">Seidizadeh et al 2024</a>].</p><p><b>Type 1C VWD.</b> VWD-causing variants associated with type 1C VWD are predominantly missense [<a class="bibr" href="#von-willebrand.REF.haberichter.2008.4979" rid="von-willebrand.REF.haberichter.2008.4979">Haberichter et al 2008</a>, <a class="bibr" href="#von-willebrand.REF.millar.2008.916" rid="von-willebrand.REF.millar.2008.916">Millar et al 2008</a>, <a class="bibr" href="#von-willebrand.REF.eikenboom.2013.2336" rid="von-willebrand.REF.eikenboom.2013.2336">Eikenboom et al 2013</a>] or other structural variants [<a class="bibr" href="#von-willebrand.REF.sadler.2023.102232" rid="von-willebrand.REF.sadler.2023.102232">Sadler et al 2023</a>] located in the D3 and A1 domains and reduce the residence time of VWF in plasma. The "Vicenza" variant, <a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvwfpathogenicvariants">p.Arg1205His</a>, is the most common of these VWD-causing variants.</p><p><b>Type 2 VWD.</b> Qualitative deficiency (type 2 VWD) almost always results from VWD-causing missense variants in functionally important areas of VWF. Most VWD-causing variants seen in types 2A, 2B, and 2M VWD are located in exon 28.</p><ul><li class="half_rhythm"><div><b>Type 2A VWD.</b> Missense variants result in a loss of high- or intermediate-molecular-weight multimers by (1) impaired dimer assembly, (2) impaired multimer assembly, (3) enhanced susceptibility to VWF cleaving protease encoded by <i>ADAMTS13</i> [<a class="bibr" href="#von-willebrand.REF.hassenpflug.2006.2339" rid="von-willebrand.REF.hassenpflug.2006.2339">Hassenpflug et al 2006</a>], and (4) intracellular retention [<a class="bibr" href="#von-willebrand.REF.schneppenheim.2010.4894" rid="von-willebrand.REF.schneppenheim.2010.4894">Schneppenheim et al 2010</a>]. All result in the loss of high-molecular-weight forms of VWF and less effective clot formation.</div></li><li class="half_rhythm"><div><b>Type 2B VWD.</b> Missense variants that allow spontaneous, inappropriate binding of VWF to platelet glycoprotein GpIbα, without the conformational change in VWF precipitated by its engagement in clotting, are associated with type 2B VWD. The platelet-VWF complex is removed from circulation and can result in mild-to-moderate thrombocytopenia in up to 50% of individuals [<a class="bibr" href="#von-willebrand.REF.castaman.2016.478" rid="von-willebrand.REF.castaman.2016.478">Castaman & Federici 2016</a>]. Higher-molecular-weight multimers bind platelets preferentially, favoring their loss. VWF platelet binding can also enhance susceptibility to the VWF cleaving protease (encoded by <i>ADAMTS13</i>), contributing to the loss of high-molecular-weight multimers.</div></li><li class="half_rhythm"><div><b>Type 2M VWD.</b> Missense variants (often in the A1 domain) that result in poor binding of VWF to GpIbα (see <a class="figpopup" href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" rid-figpopup="figvonwillebrandF3" rid-ob="figobvonwillebrandF3">Figure 3</a>) alter protein confirmation and render the domain incapable of binding GpIbα, but without the loss of high-molecular-weight multimers associated with type 2A VWD [<a class="bibr" href="#von-willebrand.REF.james.2007b.1914" rid="von-willebrand.REF.james.2007b.1914">James et al 2007b</a>]. Missense variants in the A1 domain, and less commonly the A3 domain, may also reduce affinity for subendothelial collagen types I/III (A3 domain) and IV/VI (A1 domain) [<a class="bibr" href="#von-willebrand.REF.flood.2012.1417" rid="von-willebrand.REF.flood.2012.1417">Flood et al 2012</a>, <a class="bibr" href="#von-willebrand.REF.flood.2015.2297" rid="von-willebrand.REF.flood.2015.2297">Flood et al 2015</a>].</div></li><li class="half_rhythm"><div><b>Type 2N VWD.</b> Affinity of VWF for FVIII is reduced as a result of alteration of key amino acids in the FVIII binding site or of conformational change having an indirect effect on FVIII binding by VWF (such as through lack of cleavage of the propeptide from mature VWF).</div></li></ul><p><b>Type 3 VWD.</b> Both alleles are affected by VWD-causing variants (null or missense) that result in lack of VWF secretion from the cell. Most individuals with type 3 VWD have two null alleles and therefore produce no significant quantity of VWF. Approximately 25% of alleles have missense variants (see <a class="figpopup" href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" rid-figpopup="figvonwillebrandF3" rid-ob="figobvonwillebrandF3">Figure 3</a>) [<a class="bibr" href="#von-willebrand.REF.seidizadeh.2024.2115" rid="von-willebrand.REF.seidizadeh.2024.2115">Seidizadeh et al 2024</a>]. Some may impair VWF multimerization, resulting in intracellular retention and lack of secretion into plasma.</p><p><b>Mechanism of disease causation.</b> Loss of function for types 1, 2A, 2M, 2N, and 3 VWD; gain of function for type 2B VWD</p><p><b><i>VWF</i>-specific laboratory technical considerations.</b>
|
|
<i>VWF</i> has a partial pseudogene, <i>VWFP1</i> (exons 23-34), which complicates analysis of these exons [<a class="bibr" href="#von-willebrand.REF.laffan.2021.66" rid="von-willebrand.REF.laffan.2021.66">Laffan et al 2021</a>]. Domain structure and exons encoding each VWF domain are shown in <a class="figpopup" href="/books/NBK7014/figure/von-willebrand.F3/?report=objectonly" target="object" rid-figpopup="figvonwillebrandF3" rid-ob="figobvonwillebrandF3">Figure 3</a>. Gene conversion events with <i>VWFP1</i> may impact exons 23-34 [<a class="bibr" href="#von-willebrand.REF.goodeve.2010.123" rid="von-willebrand.REF.goodeve.2010.123">Goodeve 2010</a>, <a class="bibr" href="#von-willebrand.REF.laffan.2021.66" rid="von-willebrand.REF.laffan.2021.66">Laffan et al 2021</a>]. There can be sufficient differences between <i>VWF</i> and <i>VWFP1</i> to recognize a conversion event, usually through two or more sequential sequence variants from the pseudogene sequence (<i>VWFP1</i>) [<a class="bibr" href="#von-willebrand.REF.ahmad.2019.817" rid="von-willebrand.REF.ahmad.2019.817">Ahmad et al 2019</a>]. Conversions of 6 bp to 335 bp are most commonly seen and have been reported in types 1, 2B, 2M, and 3 VWD.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figvonwillebrandTvwfpathogenicvariants"><a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object" title="Table 9. " class="img_link icnblk_img" rid-ob="figobvonwillebrandTvwfpathogenicvariants"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="von-willebrand.T.vwf_pathogenic_variants"><a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object" rid-ob="figobvonwillebrandTvwfpathogenicvariants">Table 9. </a></h4><p class="float-caption no_bottom_margin"><i>VWF</i> Pathogenic Variants Referenced in This <i>GeneReview</i> </p></div></div></div></div><div id="von-willebrand.Chapter_Notes"><h2 id="_von-willebrand_Chapter_Notes_">Chapter Notes</h2><div id="von-willebrand.Author_Notes"><h3>Author Notes</h3><p>Dr Jill Johnsen is a Professor of Medicine at the University of Washington and a physician scientist with expertise in classic hematology. Dr Johnsen sees people with bleeding disorders at the Washington Center for Bleeding Disorders and studies the genetics and biology of variation in clotting factors and blood groups (blood types). A major focus of her work is on the genetics of von Willebrand factor. Dr Johnsen's academic program is dedicated to improving the diagnosis and care of patients through research. More information and links can be found at <a href="https://hemonc.uw.edu/people/jill-johnsen" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">hemonc.uw.edu/people/jill-johnsen</a>.</p></div><div id="von-willebrand.Acknowledgments"><h3>Acknowledgments</h3><p>Dr Johnsen would like to acknowledge funding that has supported research in VWD including the National Heart Lung and Blood Institute (NIH), Octapharma, Takeda, and the Washington Center for Bleeding Disorders; funding from Hemophilia Alliance that supports genotyping for eligible people with VWD at member HTCs in the US; colleagues that have collaborated with in VWD care and research including Kerry Lannert, Shelley Fletcher, Gayle Teramura, Barbara Konkle, Rebecca Kruse-Jarres, Livia Hegerova, Dan Sabath, Tracy Tun, David Lillicrap, Dan Hampshire, Pam Christopherson, Veronica Flood, Andrew Yee, and David Ginsburg; and the many people living with and impacted by von Willebrand disease who have been critical to advancing this field and improving care.</p></div><div id="von-willebrand.Author_History"><h3>Author History</h3><p>Anne Goodeve, PhD; University of Sheffield (2009-2024)<br />Paula James, MD, FRCPC; Queen's University (2009-2024)<br />Jill Johnsen, MD (2024-present)</p></div><div id="von-willebrand.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 November 2024 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 October 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 July 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 October 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 June 2009 (et) Review posted live</div></li><li class="half_rhythm"><div>4 December 2008 (ag) Original submission</div></li></ul></div></div><div id="von-willebrand.References"><h2 id="_von-willebrand_References_">References</h2><div id="von-willebrand.Published_Guidelines__Con"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div>Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Available <a href="http://www.haematologica.org/content/98/5/667.long" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">online</a>. 2013.</div></li><li class="half_rhythm"><div>Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, Grow JM, Kouides P, Laffan M, Lavin M, Leebeek FWG, O'Brien SH, Ozelo MC, Tosetto A, Weyand AC, James PD, Kalot MA, Husainat N, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5:301-25. [<a href="https://pubmed.ncbi.nlm.nih.gov/33570647/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</div></li><li class="half_rhythm"><div>James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, R Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5:280-300. [<a href="https://pubmed.ncbi.nlm.nih.gov/33570651/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</div></li><li class="half_rhythm"><div>Johnsen J, Ginsburg D. von Willebrand Disease. In: Kaushansky K, Levi M, eds. <i>Williams Hematology Hemostasis and Thrombosis.</i> New York, NY: McGraw-Hill Education; 2017.</div></li><li class="half_rhythm"><div>Laffan M, Benson G, Farrelly C, Gomez K, Jones A, Maclean R, O'Donnell J, Lavin M. An expert consensus to define how higher standards of equitable care for von Willebrand disease can be achieved in the UK and Republic of Ireland. Haemophilia. 2023;29:819-26. [<a href="https://pubmed.ncbi.nlm.nih.gov/36877609/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</div></li><li class="half_rhythm"><div>Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, Millar CM, Keeling DM. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167:453-65. [<a href="https://pubmed.ncbi.nlm.nih.gov/25113304/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</div></li><li class="half_rhythm"><div>Platton S, Baker P, Bowyer A, Keenan C, Lawrence C, Lester W, Riddell A, Sutherland M. Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Haematology. Br J Haematol. 2024;204:1714-31. [<a href="https://pubmed.ncbi.nlm.nih.gov/38532595/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</div></li></ul></div><div id="von-willebrand.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.ahmad.2013.652">Ahmad
|
|
F, Budde
|
|
U, Jan
|
|
R, Oyen
|
|
F, Kannan
|
|
M, Saxena
|
|
R, Schneppenheim
|
|
R. Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients.
|
|
Thromb Haemost.
|
|
2013;109:652-60.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23407766" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23407766</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.ahmad.2019.817">Ahmad
|
|
F, Kannan
|
|
M, Obser
|
|
T, Budde
|
|
U, Schneppenheim
|
|
S, Saxena
|
|
R, Schneppenheim
|
|
R.
|
|
Characterization of VWF gene conversions causing von Willebrand disease.
|
|
Br J Haematol.
|
|
2019;184:817-25.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30488424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30488424</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.ahmad.2014.e311">Ahmad
|
|
F, Oyen
|
|
F, Jan
|
|
R, Budde
|
|
U, Schneppenheim
|
|
R, Saxena
|
|
R. Germline de novo mutations and linkage markers vs. DNA sequencing for carrier detection in von Willebrand disease.
|
|
Haemophilia.
|
|
2014;20:e311-7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24712919" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24712919</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.bod_.2015.1345">Bodó
|
|
I, Eikenboom
|
|
J, Montgomery
|
|
R, Patzke
|
|
J, Schneppenheim
|
|
R, Di Paola
|
|
J, et al.
|
|
Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.
|
|
J Thromb Haemost.
|
|
2015;13:1345-50.
|
|
[<a href="/pmc/articles/PMC5576173/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5576173</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25858564" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25858564</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.boisseau.2011.1567">Boisseau
|
|
P, Giraud
|
|
M, Ternisien
|
|
C, Veyradier
|
|
A, Fressinaud
|
|
E, Lefrancois
|
|
A, Bezieau
|
|
S, Fouassier
|
|
M. An unexpected transmission of von Willebrand disease type 3: the first case of maternal uniparental disomy 12.
|
|
Haematologica.
|
|
2011;96:1567-8.
|
|
[<a href="/pmc/articles/PMC3186323/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3186323</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21750090" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21750090</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.bowman.2013.512">Bowman
|
|
M, Tuttle
|
|
A, Notley
|
|
C, Brown
|
|
C, Tinlin
|
|
S, Deforest
|
|
M, Leggo
|
|
J, Blanchette
|
|
VS, Lillicrap
|
|
D, James
|
|
P, et al.
|
|
The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.
|
|
J Thromb Haemost.
|
|
2013;11:512-20.
|
|
[<a href="/pmc/articles/PMC3904644/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3904644</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23311757" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23311757</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.budde.2008.762">Budde
|
|
U, Schneppenheim
|
|
R, Eikenboom
|
|
J, Goodeve
|
|
A, Will
|
|
K, Drewke
|
|
E, Castaman
|
|
G, Rodeghiero
|
|
F, Federici
|
|
A, Batlle
|
|
J, Perez
|
|
A, Meyer
|
|
D, Mazurier
|
|
C, Goudemand
|
|
J, Ingerslev
|
|
J, Habart
|
|
D, Vorlova
|
|
Z, Holmberg
|
|
L, Lethagen
|
|
S, Pasi
|
|
J, Hill
|
|
F, Peake
|
|
I.
|
|
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).
|
|
J Thromb Haemost.
|
|
2008;6:762-71.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18315556" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18315556</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.cartwright.2020.2979">Cartwright
|
|
A, Webster
|
|
SJ, de Jong
|
|
A, Dirven
|
|
RJ, Bloomer
|
|
LDS, Al-Buhairan
|
|
AM, Budde
|
|
U, Halldén
|
|
C, Habart
|
|
D, Goudemand
|
|
J, Peake
|
|
IR, Eikenboom
|
|
JCJ, Goodeve
|
|
AC, Hampshire
|
|
DJ. Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.
|
|
Blood Adv.
|
|
2020;4:2979-90.
|
|
[<a href="/pmc/articles/PMC7362359/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7362359</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32609846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32609846</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.casa_a.2000.552">Casaña
|
|
P, Martínez
|
|
F, Haya
|
|
S, Lorenzo
|
|
JI, Espinós
|
|
C, Aznar
|
|
JA. Q1311X: a novel nonsense mutation of putative ancient origin in the von Willebrand factor gene.
|
|
Br J Haematol.
|
|
2000;111:552–5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11122100" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11122100</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.castaman.2016.478">Castaman
|
|
G, Federici
|
|
AB. Type 2B von Willebrand disease: a matter of plasma plus platelet abnormality.
|
|
Semin Thromb Hemost.
|
|
2016;42:478-82.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27148840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27148840</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.castaman.2012.632">Castaman
|
|
G, Federici
|
|
AB, Tosetto
|
|
A, La Marca
|
|
S, Stufano
|
|
F, Mannucci
|
|
PM, Rodeghiero
|
|
F. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients.
|
|
J Thromb Haemost.
|
|
2012;10:632-8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22329792" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22329792</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.castaman.2010.227">Castaman
|
|
G, Tosetto
|
|
A, Cappelletti
|
|
A, Goodeve
|
|
A, Federici
|
|
AB, Batlle
|
|
J, Meyer
|
|
D, Goudemand
|
|
J, Eikenboom
|
|
JC, Schneppenheim
|
|
R, Budde
|
|
U, Ingerslev
|
|
J, Lethagen
|
|
S, Hill
|
|
F, Peake
|
|
IR, Rodeghiero
|
|
F. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.
|
|
Thromb Res.
|
|
2010;126:227-31.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20650506" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20650506</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.chen.2022.5403">Chen
|
|
M, Shen
|
|
MC, Chang
|
|
SP, Ma
|
|
GC, Huang
|
|
YC, Lin
|
|
CY. Origin and timing of de novo variants implicated in type 2 von Willebrand disease.
|
|
J Cell Mol Med.
|
|
2022;26:5403-13.
|
|
[<a href="/pmc/articles/PMC9639050/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9639050</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36226571" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36226571</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.chornenki.2022.624">Chornenki
|
|
NLJ, Ocran
|
|
E, James
|
|
PD. Special considerations in GI bleeding in VWD patients.
|
|
Hematology Am Soc Hematol Educ Program.
|
|
2022;2022:624-30.
|
|
[<a href="/pmc/articles/PMC9820382/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9820382</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36485078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36485078</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.christopherson.2022.1576">Christopherson
|
|
PA, Haberichter
|
|
SL, Flood
|
|
VH, Perry
|
|
CL, Sadler
|
|
BE, Bellissimo
|
|
DB, Di Paola
|
|
J, Montgomery
|
|
RR; Zimmerman Program Investigators. Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program.
|
|
J Thromb Haemost.
|
|
2022;20:1576-88.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35343054" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35343054</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.connell.2021.301">Connell
|
|
NT, Flood
|
|
VH, Brignardello-Petersen
|
|
R, Abdul-Kadir
|
|
R, Arapshian
|
|
A, Couper
|
|
S, Grow
|
|
JM, Kouides
|
|
P, Laffan
|
|
M, Lavin
|
|
M, Leebeek
|
|
FWG, O'Brien
|
|
SH, Ozelo
|
|
MC, Tosetto
|
|
A, Weyand
|
|
AC, James
|
|
PD, Kalot
|
|
MA, Husainat
|
|
N, Mustafa
|
|
RA. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
|
|
Blood Adv.
|
|
2021;5:301-25.
|
|
[<a href="/pmc/articles/PMC7805326/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7805326</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33570647" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33570647</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.cumming.2006.630">Cumming
|
|
A, Grundy
|
|
P, Keeney
|
|
S, Lester
|
|
W, Enayat
|
|
S, Guilliatt
|
|
A, Bowen
|
|
D, Pasi
|
|
J, Keeling
|
|
D, Hill
|
|
F, Bolton-Maggs
|
|
PH, Hay
|
|
C, Collins
|
|
P. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.
|
|
Thromb Haemost.
|
|
2006;96:630-41.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17080221" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17080221</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.doherty.2023.302">Doherty
|
|
D, Lavin
|
|
M, Byrne
|
|
M, Nolan
|
|
M, O'Sullivan
|
|
JM, Ryan
|
|
K, O'Connell
|
|
NM, Haberichter
|
|
SL, Christopherson
|
|
PA, Di Paola
|
|
J, James
|
|
PD, O'Donnell
|
|
JS. Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance.
|
|
Blood Adv.
|
|
2023;7:302-8.
|
|
[<a href="/pmc/articles/PMC9898599/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9898599</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35523118" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35523118</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.eikenboom.2013.2336">Eikenboom
|
|
J, Federici
|
|
AB, Dirven
|
|
RJ, Castaman
|
|
G, Rodeghiero
|
|
F, Budde
|
|
U, Schneppenheim
|
|
R, Batlle
|
|
J, Canciani
|
|
MT, Goudemand
|
|
J, Peake
|
|
I, Goodeve
|
|
A, et al.
|
|
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
|
|
Blood.
|
|
2013;121:2336-9.
|
|
[<a href="/pmc/articles/PMC4191434/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4191434</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23349392" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23349392</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.federici.2013.191">Federici
|
|
AB, Budde
|
|
U, Castaman
|
|
G, Rand
|
|
JH, Tiede
|
|
A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.
|
|
Semin Thromb Hemost.
|
|
2013;39:191-201.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23397553" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23397553</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.federici.2009.526">Federici
|
|
AB, Mannucci
|
|
PM, Castaman
|
|
G, Baronciani
|
|
L, Bucciarelli
|
|
P, Canciani
|
|
MT, Pecci
|
|
A, Lenting
|
|
PJ, De Groot
|
|
PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.
|
|
Blood
|
|
2009;113:526-34.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18805962" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18805962</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.flood.2012.1417">Flood
|
|
VH, Gill
|
|
JC, Christopherson
|
|
PA, Bellissimo
|
|
DB, Friedman
|
|
KD, Haberichter
|
|
SL, Lentz
|
|
SR, Montgomery
|
|
RR. Critical von Willebrand factor A1 domain residues influence type VI collagen binding.
|
|
J Thromb Haemost.
|
|
2012;10:1417-24.
|
|
[<a href="/pmc/articles/PMC3809952/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3809952</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22507569" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22507569</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.flood.2015.2297">Flood
|
|
VH, Schlauderaff
|
|
AC, Haberichter
|
|
SL, Slobodianuk
|
|
TL, Jacobi
|
|
PM, Bellissimo
|
|
DB, Christopherson
|
|
PA, Friedman
|
|
KD, Gill
|
|
JC, Hoffmann
|
|
RG, Montgomery
|
|
RR, et al.
|
|
Crucial role for the VWF A1 domain in binding to type IV collagen.
|
|
Blood.
|
|
2015;125:2297-304.
|
|
[<a href="/pmc/articles/PMC4383803/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4383803</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25662333" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25662333</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.franchini.2020.2032">Franchini
|
|
M, Mannucci
|
|
PM. Acquired von Willebrand syndrome: focused for hematologists.
|
|
Haematologica.
|
|
2020;105:2032-7.
|
|
[<a href="/pmc/articles/PMC7395262/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7395262</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32554559" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32554559</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.franchini.2018.590">Franchini
|
|
M, Mannucci
|
|
PM. Alloantibodies in von Willebrand Disease.
|
|
Semin Thromb Hemost.
|
|
2018;44:590-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29165738" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29165738</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.franchini.2014.427">Franchini
|
|
M, Mannucci
|
|
PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease.
|
|
Thromb Haemost.
|
|
2014;112:427-31.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24898873" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24898873</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.franchini.2016.825">Franchini
|
|
M, Mannucci
|
|
PM. Von Willebrand factor (Vonvendi(R)): the first recombinant product licensed for the treatment of von Willebrand disease.
|
|
Expert Rev Hematol.
|
|
2016;9:825-30.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27427955" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27427955</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.fu.2024">Fu
|
|
A, Kazmirchuk
|
|
TDD, Bradbury-Jost
|
|
C, Golshani
|
|
A, Othman
|
|
M. Platelet-type von Willebrand disease: complex pathophysiology and insights on novel therapeutic and diagnostic strategies.
|
|
Semin Thromb Hemost.
|
|
2024. Epub ahead of print.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/39191406" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 39191406</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.goodeve.2016.678">Goodeve
|
|
A.
|
|
Diagnosing von Willebrand disease: genetic analysis.
|
|
Hematology Am Soc Hematol Educ Program.
|
|
2016;2016:678-82.
|
|
[<a href="/pmc/articles/PMC6065508/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6065508</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27913546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27913546</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.goodeve.2007.112">Goodeve
|
|
A, Eikenboom
|
|
J, Castaman
|
|
G, Rodeghiero
|
|
F, Federici
|
|
AB, Batlle
|
|
J, Meyer
|
|
D, Mazurier
|
|
C, Goudemand
|
|
J, Schneppenheim
|
|
R, Budde
|
|
U, Ingerslev
|
|
J, Habart
|
|
D, Vorlova
|
|
Z, Holmberg
|
|
L, Lethagen
|
|
S, Pasi
|
|
J, Hill
|
|
F, Hashemi Soteh
|
|
M, Baronciani
|
|
L, Hallden
|
|
C, Guilliatt
|
|
A, Lester
|
|
W, Peake
|
|
I. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).
|
|
Blood.
|
|
2007;109:112-21.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16985174" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16985174</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.goodeve.2010.123">Goodeve
|
|
AC. The genetic basis of von Willebrand disease.
|
|
Blood Rev.
|
|
2010;24:123-34.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20409624" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20409624</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.gupta.2016.e431">Gupta
|
|
S, Heiman
|
|
M, Duncan
|
|
N, Hinckley
|
|
J, Di Paola
|
|
J, Shapiro
|
|
AD. Variable bleeding phenotype in an Amish pedigree with von Willebrand disease.
|
|
Am J Hematol.
|
|
2016;91:E431–5.
|
|
[<a href="/pmc/articles/PMC5031525/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5031525</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27414491" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27414491</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.haberichter.2015.1753">Haberichter
|
|
SL. Von Willebrand factor propeptide: biology and clinical utility.
|
|
Blood.
|
|
2015;126:1753-61.
|
|
[<a href="/pmc/articles/PMC4600015/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4600015</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26215113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26215113</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.haberichter.2008.4979">Haberichter
|
|
SL, Castaman
|
|
G, Budde
|
|
U, Peake
|
|
I, Goodeve
|
|
A, Rodeghiero
|
|
F, Federici
|
|
AB, Batlle
|
|
J, Meyer
|
|
D, Mazurier
|
|
C, Goudemand
|
|
J, Eikenboom
|
|
J, Schneppenheim
|
|
R, Ingerslev
|
|
J, Vorlova
|
|
Z, Habart
|
|
D, Holmberg
|
|
L, Lethagen
|
|
S, Pasi
|
|
J, Hill
|
|
FG, Montgomery
|
|
RR. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
|
|
Blood.
|
|
2008;111:4979-85.
|
|
[<a href="/pmc/articles/PMC2384129/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2384129</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18344424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18344424</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.hamilton.2011.501">Hamilton
|
|
A, Ozelo
|
|
M, Leggo
|
|
J, Notley
|
|
C, Brown
|
|
H, Frontroth
|
|
JP, Angelillo-Scherrer
|
|
A, Baghaei
|
|
F, Enayat
|
|
SM, Favaloro
|
|
E, Lillicrap
|
|
D, Othman
|
|
M. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.
|
|
Thromb Haemost.
|
|
2011;105:501-8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21301777" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21301777</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.hassenpflug.2006.2339">Hassenpflug
|
|
WA, Budde
|
|
U, Obser
|
|
T, Angerhaus
|
|
D, Drewke
|
|
E, Schneppenheim
|
|
S, Schneppenheim
|
|
R. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.
|
|
Blood.
|
|
2006;107:2339-45.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16322474" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16322474</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.huang.2022.389">Huang
|
|
SJ, Amendola
|
|
LM, Sternen
|
|
DL. Variation among DNA banking consent forms: points for clinicians to bank on.
|
|
J Community Genet.
|
|
2022;13:389-97.
|
|
[<a href="/pmc/articles/PMC9314484/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9314484</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35834113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35834113</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.james.2015.81">James
|
|
AH, Konkle
|
|
BA, Kouides
|
|
P, Ragni
|
|
MV, Thames
|
|
B, Gupta
|
|
S, Sood
|
|
S, Fletcher
|
|
SK, Philipp
|
|
CS. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.
|
|
Haemophilia.
|
|
2015;21:81-7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25333737" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25333737</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.james.2021.280">James
|
|
PD, Connell
|
|
NT, Ameer
|
|
B, Di Paola
|
|
J, Eikenboom
|
|
J, Giraud
|
|
N, Haberichter
|
|
S, Jacobs-Pratt
|
|
V, Konkle
|
|
B, McLintock
|
|
C, McRae
|
|
S, R Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.
|
|
Blood Adv.
|
|
2021;5:280-300.
|
|
[<a href="/pmc/articles/PMC7805340/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7805340</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33570651" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33570651</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.james.2007a.145">James
|
|
PD, Notley
|
|
C, Hegadorn
|
|
C, Leggo
|
|
J, Tuttle
|
|
A, Tinlin
|
|
S, Brown
|
|
C, Andrews
|
|
C, Labelle
|
|
A, Chirinian
|
|
Y, O'Brien
|
|
L, Othman
|
|
M, Rivard
|
|
G, Rapson
|
|
D, Hough
|
|
C, Lillicrap
|
|
D. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study.
|
|
Blood.
|
|
2007a;109:145-54.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17190853" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17190853</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.james.2007b.1914">James
|
|
PD, Notley
|
|
C, Hegadorn
|
|
C, Poon
|
|
MC, Walker
|
|
I, Rapson
|
|
D, Lillicrap
|
|
D. Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.
|
|
J Thromb Haemost.
|
|
2007b;5:1914-22.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17596142" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17596142</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.johnsen.2022.2022">Johnsen
|
|
JM, Fletcher
|
|
SN, Dove
|
|
A, McCracken
|
|
H, Martin
|
|
BK, Kircher
|
|
M, Josephson
|
|
NC, Shendure
|
|
J, Ruuska
|
|
SE, Valentino
|
|
LA, Pierce
|
|
GF, Watson
|
|
C, Cheng
|
|
D, Recht
|
|
M, Konkle
|
|
BA. Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States.
|
|
J Thromb Haemost.
|
|
2022;20:2022-34.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35770352" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35770352</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.johnsen.2022.1568">Johnsen
|
|
JM, MacKinnon
|
|
HJ. JTH in clinic - obstetric bleeding: VWD and other inherited bleeding disorders.
|
|
J Thromb Haemost.
|
|
2022;20:1568-75.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/35621921" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35621921</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.j_nsson.2017.519">Jónsson
|
|
H, Sulem
|
|
P, Kehr
|
|
B, Kristmundsdottir
|
|
S, Zink
|
|
F, Hjartarson
|
|
E, Hardarson
|
|
MT, Hjorleifsson
|
|
KE, Eggertsson
|
|
HP, Gudjonsson
|
|
SA, Ward
|
|
LD, Arnadottir
|
|
GA, Helgason
|
|
EA, Helgason
|
|
H, Gylfason
|
|
A, Jonasdottir
|
|
A, Jonasdottir
|
|
A, Rafnar
|
|
T, Frigge
|
|
M, Stacey
|
|
SN, Th Magnusson
|
|
O, Thorsteinsdottir
|
|
U, Masson
|
|
G, Kong
|
|
A, Halldorsson
|
|
BV, Helgason
|
|
A, Gudbjartsson
|
|
DF, Stefansson
|
|
K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland.
|
|
Nature.
|
|
2017;549:519-22.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28959963" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28959963</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.kalot.2022a.3735">Kalot
|
|
MA, Husainat
|
|
N, Abughanimeh
|
|
O, Diab
|
|
O, El Alayli
|
|
A, Tayiem
|
|
S, Madoukh
|
|
B, Dimassi
|
|
A, Qureini
|
|
A, Ameer
|
|
B, Eikenboom
|
|
J, Giraud
|
|
N, Haberichter
|
|
S, Jacobs-Pratt
|
|
V, Konkle
|
|
BA, McRae
|
|
S, Montgomery
|
|
R, O'Donnell
|
|
JS, Brignardello-Petersen
|
|
R, Flood
|
|
V, Connell
|
|
NT, James
|
|
P, Mustafa
|
|
RA. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.
|
|
Blood Adv.
|
|
2022a;6:3735-45.
|
|
[<a href="/pmc/articles/PMC9631556/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9631556</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35192687" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35192687</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.kalot.2022b.62">Kalot
|
|
MA, Husainat
|
|
N, El Alayli
|
|
A, Abughanimeh
|
|
O, Diab
|
|
O, Tayiem
|
|
S, Madoukh
|
|
B, Dimassi
|
|
AB, Qureini
|
|
A, Ameer
|
|
B, Eikenboom
|
|
JCJ, Giraud
|
|
N, McLintock
|
|
C, McRae
|
|
S, Montgomery
|
|
RR, O'Donnell
|
|
JS, Scappe
|
|
N, Sidonio
|
|
RF, Brignardello-Petersen
|
|
R, Flood
|
|
VH, Connell
|
|
NT, James
|
|
PD, Mustafa
|
|
RA. Von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis.
|
|
Blood Adv.
|
|
2022b;6:62-71.
|
|
[<a href="/pmc/articles/PMC8753202/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8753202</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34610118" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34610118</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.kasatkar.2014.e92575">Kasatkar
|
|
P, Shetty
|
|
S, Ghosh
|
|
K. Genetic heterogeneity in a large cohort of Indian type 3 von Willebrand disease patients.
|
|
PLoS One.
|
|
2014;9:e92575.
|
|
[<a href="/pmc/articles/PMC3967998/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3967998</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24675615" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24675615</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.laffan.2021.66">Laffan
|
|
M, Sathar
|
|
J, Johnsen
|
|
JM. Von Willebrand disease: diagnosis and treatment, treatment of women, and genomic approach to diagnosis.
|
|
Haemophilia.
|
|
2021;27
|
|
Suppl 3:66-74.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32578345" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32578345</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.larsen.2013.590">Larsen
|
|
DM, Haberichter
|
|
SL, Gill
|
|
JC, Shapiro
|
|
AD, Flood
|
|
VH. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
|
|
Haemophilia.
|
|
2013;19:590-4.
|
|
[<a href="/pmc/articles/PMC3688679/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3688679</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23496210" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23496210</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.lavin.2022.82">Lavin
|
|
M, Sánchez Luceros
|
|
A, Kouides
|
|
P, Abdul-Kadir
|
|
R, O'Donnell
|
|
JS, Baker
|
|
RI, Othman
|
|
M, Haberichter
|
|
SL; ISTH Von Willebrand Factor and Women’s Health Scientific Subcommittees. Examining international practices in the management of pregnant women with von Willebrand disease.
|
|
J Thromb Haemost.
|
|
2022;20:82-91.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/34661341" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34661341</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.leissinger.2014.158">Leissinger
|
|
C, Carcao
|
|
M, Gill
|
|
JC, Journeycake
|
|
J, Singleton
|
|
T, Valentino
|
|
L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders.
|
|
Haemophilia.
|
|
2014;20:158-67.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23937614" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23937614</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.lim.2024.470">Lim
|
|
MY, Rodgers
|
|
GM, Branch
|
|
DW, Simonsen
|
|
SE. Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: outcomes at a single-institution cohort study.
|
|
Haemophilia.
|
|
2024;30:470-7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/38343098" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38343098</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.maas.2022.316">Maas
|
|
DPMSM, Atiq
|
|
F, Blijlevens
|
|
NMA, Brons
|
|
PPT, Krouwel
|
|
S, Laros-van Gorkom
|
|
BAP, Leebeek
|
|
FWG, Nieuwenhuizen
|
|
L, Schoormans
|
|
SCM, Simons
|
|
A, Meijer
|
|
D, van Heerde
|
|
WL, Schols
|
|
SEM. Von Willebrand disease type 2M: correlation between genotype and phenotype.
|
|
J Thromb Haemost.
|
|
2022;20:316-27.
|
|
[<a href="/pmc/articles/PMC9299039/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9299039</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34758185" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34758185</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.metjian.2009.918">Metjian
|
|
AD, Wang
|
|
C, Sood
|
|
SL, Cuker
|
|
A, Peterson
|
|
SM, Soucie
|
|
JM, Konkle
|
|
BA. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease.
|
|
Haemophilia.
|
|
2009;15:918-25.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19473418" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19473418</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.millar.2008.916">Millar
|
|
CM, Riddell
|
|
AF, Brown
|
|
SA, Starke
|
|
R, Mackie
|
|
I, Bowen
|
|
DJ, Jenkins
|
|
PV, van Mourik
|
|
JA. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
|
|
Thromb Haemost.
|
|
2008;99:916-24.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18449422" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18449422</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.mital.2016.1337">Mital
|
|
A.
|
|
Acquired von Willebrand syndrome.
|
|
Adv Clin Exp Med.
|
|
2016;25:1337-44.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28028990" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28028990</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.nichols.2008.171">Nichols
|
|
WL, Hultin
|
|
MB, James
|
|
AH, Manco-Johnson
|
|
MJ, Montgomery
|
|
RR, Ortel
|
|
TL, Rick
|
|
ME, Sadler
|
|
JE, Weinstein
|
|
M, Yawn
|
|
BP. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
|
|
Haemophilia.
|
|
2008;14:171-232.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18315614" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18315614</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.othman.2016.411">Othman
|
|
M, Kaur
|
|
H, Favaloro
|
|
EJ, Lillicrap
|
|
D, Di Paola
|
|
J, Harrison
|
|
P, Gresele
|
|
P, Willebrand
|
|
D, Platelet
|
|
P, et al.
|
|
Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH.
|
|
J Thromb Haemost.
|
|
2016;14:411-4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26882161" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26882161</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.punt.2020.100633">Punt
|
|
MC, Waning
|
|
ML, Mauser-Bunschoten
|
|
EP, Kruip
|
|
MJHA, Eikenboom
|
|
J, Nieuwenhuizen
|
|
L, Makelburg
|
|
ABU, Driessens
|
|
MHE, Duvekot
|
|
JJ, Peters
|
|
M, Middeldorp
|
|
JM, Bloemenkamp
|
|
KWM, Schutgens
|
|
REG, Lely
|
|
AT, Van Galen
|
|
KPM. Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: a systematic review.
|
|
Blood Rev.
|
|
2020;39:100633.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31718817" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31718817</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.ragni.2016.397">Ragni
|
|
MV, Machin
|
|
N, Malec
|
|
LM, James
|
|
AH, Kessler
|
|
CM, Konkle
|
|
BA, Kouides
|
|
PA, Neff
|
|
AT, Philipp
|
|
CS, Brambilla
|
|
DJ. Von Willebrand factor for menorrhagia: a survey and literature review.
|
|
Haemophilia.
|
|
2016;22:397-402.
|
|
[<a href="/pmc/articles/PMC4874860/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4874860</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26843404" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26843404</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.saadalla.2023.580">Saadalla
|
|
A, Seheult
|
|
J, Pruthi
|
|
RK, Chen
|
|
D. Von Willebrand factor multimer analysis and classification: a comprehensive review and updates.
|
|
Semin Thromb Hemost.
|
|
2023;49:580-91.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/36174612" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36174612</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.sadler.2023.102232">Sadler
|
|
B, Christopherson
|
|
PA, Perry
|
|
CL, Bellissimo
|
|
DB, Haberichter
|
|
SL, Haller
|
|
G, Antunes
|
|
L, Flood
|
|
VH, Di Paola
|
|
J, Montgomery
|
|
RR; Zimmerman Program Investigators. Characterization of copy-number variants in a large cohort of patients with von Willebrand disease reveals a relationship between disrupted regions and disease type.
|
|
Res Pract Thromb Haemost.
|
|
2023;7:102232.
|
|
[<a href="/pmc/articles/PMC10704516/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10704516</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38077814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38077814</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.schneppenheim.2010.4894">Schneppenheim
|
|
R, Michiels
|
|
JJ, Obser
|
|
T, Oyen
|
|
F, Pieconka
|
|
A, Schneppenheim
|
|
S, Will
|
|
K, Zieger
|
|
B, Budde
|
|
U. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.
|
|
Blood.
|
|
2010;115:4894-901.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20351307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20351307</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.seidizadeh.2024.2115">Seidizadeh
|
|
O, Baronciani
|
|
L, Lillicrap
|
|
D, Peyvandi
|
|
F. Application of genetic testing for the diagnosis of von Willebrand disease.
|
|
J Thromb Haemost.
|
|
2024;22:2115-28.
|
|
[<a href="/pmc/articles/PMC11548015/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11548015</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38762018" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38762018</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.seidizadeh.2021.909">Seidizadeh
|
|
O, Peyvandi
|
|
F, Mannucci
|
|
PM. Von Willebrand disease type 2N: an update.
|
|
J Thromb Haemost.
|
|
2021;19:909-16.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33497541" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33497541</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.shen.2016.36">Shen
|
|
MC, Chen
|
|
M, Ma
|
|
GC, Chang
|
|
SP, Lin
|
|
CY, Lin
|
|
BD, Hsieh
|
|
HN. De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD.
|
|
Thromb J.
|
|
2016;14(Suppl 1):36.
|
|
[<a href="/pmc/articles/PMC5056463/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5056463</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27766062" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27766062</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.stenson.2020.1197">Stenson
|
|
PD, Mort
|
|
M, Ball
|
|
EV, Chapman
|
|
M, Evans
|
|
K, Azevedo
|
|
L, Hayden
|
|
M, Heywood
|
|
S, Millar
|
|
DS, Phillips
|
|
AD, Cooper
|
|
DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting.
|
|
Hum Genet.
|
|
2020;139:1197-207.
|
|
[<a href="/pmc/articles/PMC7497289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7497289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32596782" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32596782</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.stockschlaeder.2014.206">Stockschlaeder
|
|
M, Schneppenheim
|
|
R, Budde
|
|
U.
|
|
Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.
|
|
Blood Coagul Fibrinolysis.
|
|
2014;25:206-16.
|
|
[<a href="/pmc/articles/PMC3969155/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3969155</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24448155" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24448155</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.sucker.2009.177">Sucker
|
|
C, Michiels
|
|
JJ, Zotz
|
|
RB. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
|
|
Acta Haematol.
|
|
2009;121:177-82.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/19506364" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19506364</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.tosetto.2020.2145">Tosetto
|
|
A, Badiee
|
|
Z, Baghaipour
|
|
MR, Baronciani
|
|
L, Battle
|
|
J, Berntorp
|
|
E, Bodó
|
|
I, Budde
|
|
U, Castaman
|
|
G, Eikenboom
|
|
JCJ, Eshghi
|
|
P, Ettorre
|
|
C, Goodeve
|
|
A, Goudemand
|
|
J, Hay
|
|
CRM, Hoorfar
|
|
H, Karimi
|
|
M, Keikhaei
|
|
B, Lassila
|
|
R, Leebeek
|
|
FWG, Lopez Fernandez
|
|
MF, Mannucci
|
|
PM, Mazzucconi
|
|
MG, Morfini
|
|
M, Oldenburg
|
|
J, Peake
|
|
I, Parra Lòpez
|
|
R, Peyvandi
|
|
F, Schneppenheim
|
|
R, Tiede
|
|
A, Toogeh
|
|
G, Trossaert
|
|
M, Zekavat
|
|
O, Zetterberg
|
|
EMK, Federici
|
|
AB. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
|
|
J Thromb Haemost.
|
|
2020;18:2145-54.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32379400" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32379400</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.van_meegeren.2015.e375">van Meegeren
|
|
ME, Mancini
|
|
TL, Schoormans
|
|
SC, van Haren
|
|
BJ, van Duren
|
|
C, Diekstra
|
|
A, Laros-van Gorkom
|
|
BA, Brons
|
|
PP, Simons
|
|
A, Hoefsloot
|
|
L, van Heerde
|
|
WL. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype.
|
|
Haemophilia.
|
|
2015;21:e375-83.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26207643" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26207643</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.veyradier.2016.e3038">Veyradier
|
|
A, Boisseau
|
|
P, Fressinaud
|
|
E, Caron
|
|
C, Ternisien
|
|
C, Giraud
|
|
M, Zawadzki
|
|
C, Trossaert
|
|
M, Itzhar-Baikian
|
|
N, Dreyfus
|
|
M, d'Oiron
|
|
R, Borel-Derlon
|
|
A, Susen
|
|
S, Bezieau
|
|
S, Denis
|
|
CV, Goudemand
|
|
J, et al.
|
|
A laboratory phenotype/genotype correlation of 1167 French patients from 670 families with von Willebrand disease: a new epidemiologic picture.
|
|
Medicine (Baltimore). 2016;95:e3038.
|
|
[<a href="/pmc/articles/PMC4839904/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4839904</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26986123" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26986123</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.weyand.2021.1085">Weyand
|
|
AC, Flood
|
|
VH. Von Willebrand Disease: current status of diagnosis and management.
|
|
Hematol Oncol Clin North Am.
|
|
2021;35:1085-101.
|
|
[<a href="/pmc/articles/PMC8919990/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8919990</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34400042" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34400042</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="von-willebrand.REF.yadegari.2012.662">Yadegari
|
|
H, Driesen
|
|
J, Pavlova
|
|
A, Biswas
|
|
A, Hertfelder
|
|
HJ, Oldenburg
|
|
J. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
|
|
Thromb Haemost.
|
|
2012;108:662-71.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22871923" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22871923</span></a>]</div></p></li></ul></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK7014_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Jill Johnsen</span>, MD<div class="affiliation small">Division of Hematology and Oncology, Department of Medicine;<br />Institute for Stem Cell & Regenerative Medicine;<br />Center for Cardiovascular Biology<br />University of Washington<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wu@nesnhojj" class="oemail">ude.wu@nesnhojj</a></div></div></div><h3>Publication History</h3><p class="small">Initial Posting: <span itemprop="datePublished">June 4, 2009</span>; Last Update: <span itemprop="dateModified">November 14, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2025, University of Washington, Seattle. GeneReviews is
|
|
a registered trademark of the University of Washington, Seattle. All rights
|
|
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
|
|
hereby granted to reproduce, distribute, and translate copies of content materials for
|
|
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2025 University of
|
|
Washington) are included with each copy; (ii) a link to the original material is provided
|
|
whenever the material is published elsewhere on the Web; and (iii) reproducers,
|
|
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
|
|
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
|
|
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
|
|
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div></div><h3>Publisher</h3><p><a href="http://www.washington.edu" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">University of Washington, Seattle</a>, Seattle (WA)</p><h3>NLM Citation</h3><p>Johnsen J. Von Willebrand Disease. 2009 Jun 4 [Updated 2024 Nov 14]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/gene/vhl/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/gene/wac-id/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobvonwillebrandTvonwillebranddisease"><div id="von-willebrand.T.von_willebrand_disease" class="table"><div class="caption"><p>Von Willebrand Disease: Phenotypic Spectrum</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.von_willebrand_disease_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Von Willebrand Disease Subtype</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Partial quantitative deficiency of functionally normal VWF</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 1 VWD<br />Type 1C VWD</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Qualitative defect in one or more VWF functions; divided into four subtypes depending on which VWF function is perturbed</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 2A VWD<br />Type 2B VWD<br />Type 2M VWD<br />Type 2N VWD</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Undetectable VWF levels</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 3 VWD</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VWD = von Willebrand disease; VWF = von Willebrand factor</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTclassificationofvwdb"><div id="von-willebrand.T.classification_of_vwd_b" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Classification of VWD Based on Specific Laboratory Tests</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.classification_of_vwd_b/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.classification_of_vwd_b_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWD Type</th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWF:Act <sup>1, 2</sup></th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWF:Ag <sup>2</sup></th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWF:Act-to-VWF:Ag Ratio</th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWF:CB <sup>2</sup></th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FVIII IU/dL <sup>2</sup></th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multimer Pattern</th><th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">≥0.7</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low or normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Essentially normal <sup>3</sup></td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal VWF half-life after desmopressin</td></tr><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1C</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">≥0.7</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low or normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Essentially normal <sup>3</sup></td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">↓ VWF half-life after desmopressin</td></tr><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2A</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; rarely, can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><0.7</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; rarely, can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low or normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal; ↓ HMW</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2B</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; rarely, can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Often <0.7; can be ≥0.7</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low or normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Often abnormal; ↓ HMW</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classification requires identification of VWD-causing <i>VWF</i> variant or ↑ RIPA; <sup>4</sup> often ↓ platelet count <sup>5</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2M</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; rarely, can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><0.7</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low; can be normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low or normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Essentially normal <sup>3</sup></td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classification requires ↓ VWF:Act-to-VWF:Ag ratio or ↓ VWF:CB-to-VWF:Ag ratio (<0.7) <sup>6</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2N</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal; can be low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal; can be low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">≥0.7</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal; can be low</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><40</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classification requires FVIII activity < VWF:Ag & ↓ VWF:FVIIIB or identification of VWD-causing <i>VWF</i> variants <sup>7</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><10</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No detectable VWF</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">FVIII = factor VIII; HMW = high-molecular-weight VWF multimers; NA = not applicable; RIPA = ristocetin-induced platelet agglutination; VWD = von Willebrand disease; VWF = von Willebrand factor; VWF:Act = platelet-dependent VWF activity; VWF:Ag = VWF antigen; VWF:CB = VWF collagen binding; VWF:FVIIIB = binding of FVIII by VWF</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.1.1"><p class="no_margin">VWF:Act assays include VWF:RCo, VWF:GPIbR, and VWF:GPIbM. VWF activity assays that do not use ristocetin are preferred when available [<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al 2021</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="von-willebrand.TF.1.2"><p class="no_margin">"Low" refers to VWF:Act <50 IU/dL, VWF:Ag <50 IU/dL, VWF:CB <50 IU/dL, or FVIII activity below the laboratory reference range (usually <50 IU/dL).</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="von-willebrand.TF.1.3"><p class="no_margin">All sizes of multimers are present, but there may be subtle abnormalities in multimer pattern.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="von-willebrand.TF.1.4"><p class="no_margin">Clinical presentation of type 2B VWD is identical to platelet-type VWD (PT-VWD). Type 2B VWD is distinguished from PT-VWD using molecular genetic testing or specialized RIPA mixing studies.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="von-willebrand.TF.1.5"><p class="no_margin">Thrombocytopenia and decrease in high-molecular-weight VWF multimers usually occur together. In those with a normal platelet count and normal VWF multimer distribution, the predisposition to thrombocytopenia and abnormal VWF multimer distribution is often unmasked by physical stressors.</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="von-willebrand.TF.1.6"><p class="no_margin">Reduction in the ability of VWF to bind to collagen. Collagen types I/III are bound by the VWF A3 domain, while collagen types IV and VI are bound by the VWF A1 domain. Most clinical laboratories do not have assays to test VWF binding to all relevant collagen types.</p></div></dd></dl><dl class="bkr_refwrap"><dt>7. </dt><dd><div id="von-willebrand.TF.1.7"><p class="no_margin">Clinical presentation of type 2N VWD is similar to <a href="/books/n/gene/hemo-a/?report=reader">hemophilia A</a> except that inheritance of type 2N VWD is autosomal recessive and hemophilia A is X-linked. Type 2N VWD can be distinguished from hemophilia A through molecular genetic testing or decreased VWF:FVIIIB.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTmoleculargenetictesti"><div id="von-willebrand.T.molecular_genetic_testi" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in von Willebrand Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.molecular_genetic_testi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.molecular_genetic_testi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_2" style="text-align:left;vertical-align:middle;">VWD subtype</th><th id="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of VWD-Causative Variants <sup>2</sup> Identified by Method</th></tr><tr><th headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3" id="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis <sup>3</sup></th><th headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3" id="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted deletion/duplication analysis <sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>VWF</i>
|
|
</td><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 1 VWD w/VWF 30-50 IU/dL</td><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3 hd_h_von-willebrand.T.molecular_genetic_testi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%-60%</td><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3 hd_h_von-willebrand.T.molecular_genetic_testi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare <sup>5</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Type 1 VWD w/VWF ≤30 IU/dL</td><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3 hd_h_von-willebrand.T.molecular_genetic_testi_1_1_2_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">80%-90% <sup>6, 7</sup></td><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_3 hd_h_von-willebrand.T.molecular_genetic_testi_1_1_2_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">≤6% <sup>6, 7</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Type 2 VWD</td></tr><tr><td headers="hd_h_von-willebrand.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Type 3 VWD</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VWD = von Willebrand disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.2.1"><p class="no_margin">See <a href="/books/NBK7014/?report=reader#von-willebrand.molgen.TA">Table A. Genes and Databases</a> for chromosome locus and protein.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="von-willebrand.TF.2.2"><p class="no_margin">See <a href="#von-willebrand.Molecular_Genetics">Molecular Genetics</a> for information on variants detected in this gene.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="von-willebrand.TF.2.3"><p class="no_margin">Sequence analysis detects missense, nonsense, splice site variants, and small insertions or deletions. Sequence analysis should include regulatory regions and the <i>VWF</i> promotor. Larger deletions, duplications, structural variants including pseudogene conversions, and non-coding deep intronic variants are not often detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/?report=reader">here</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="von-willebrand.TF.2.4"><p class="no_margin">Gene-targeted deletion/duplication methods can detect deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, custom analyses of next generation sequencing data, multiplex ligation-dependent probe amplification (MLPA), comparative genomic hybridization (CGH), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="von-willebrand.TF.2.5"><p class="no_margin"><a class="bibr" href="#von-willebrand.REF.cartwright.2020.2979" rid="von-willebrand.REF.cartwright.2020.2979">Cartwright et al [2020]</a>, <a class="bibr" href="#von-willebrand.REF.sadler.2023.102232" rid="von-willebrand.REF.sadler.2023.102232">Sadler et al [2023]</a></p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="von-willebrand.TF.2.6"><p class="no_margin"><a class="bibr" href="#von-willebrand.REF.cumming.2006.630" rid="von-willebrand.REF.cumming.2006.630">Cumming et al [2006]</a>, <a class="bibr" href="#von-willebrand.REF.goodeve.2007.112" rid="von-willebrand.REF.goodeve.2007.112">Goodeve et al [2007]</a>, <a class="bibr" href="#von-willebrand.REF.james.2007a.145" rid="von-willebrand.REF.james.2007a.145">James et al [2007a]</a>, <a class="bibr" href="#von-willebrand.REF.yadegari.2012.662" rid="von-willebrand.REF.yadegari.2012.662">Yadegari et al [2012]</a>, <a class="bibr" href="#von-willebrand.REF.veyradier.2016.e3038" rid="von-willebrand.REF.veyradier.2016.e3038">Veyradier et al [2016]</a>, <a class="bibr" href="#von-willebrand.REF.laffan.2021.66" rid="von-willebrand.REF.laffan.2021.66">Laffan et al [2021]</a>, <a class="bibr" href="#von-willebrand.REF.kalot.2022b.62" rid="von-willebrand.REF.kalot.2022b.62">Kalot et al [2022b]</a>, and data derived from the subscription-based professional view of Human Gene Mutation Database [<a class="bibr" href="#von-willebrand.REF.stenson.2020.1197" rid="von-willebrand.REF.stenson.2020.1197">Stenson et al 2020</a>]</p></div></dd></dl><dl class="bkr_refwrap"><dt>7. </dt><dd><div id="von-willebrand.TF.2.7"><p class="no_margin">Sequencing and analysis of <i>VWF</i> exons 23 to 34 is complicated by the presence of a partial pseudogene, <i>VWFP1</i>, on chromosome 22 (see <a href="#von-willebrand.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTclarificationsandchan"><div id="von-willebrand.T.clarifications_and_chan" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Clarifications and Changes in von Willebrand Disease Nomenclature</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.clarifications_and_chan/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.clarifications_and_chan_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Term</th><th id="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Current Term &/or Definition</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Platelet-dependent VWF activity</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refers to VWF activity w/regard to platelets, incl VWF:RCo, VWF:GPIbR, and VWF:GPIbM <sup>1</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 1C VWD</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refers to type 1 VWD w/accelerated VWF clearance</td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWF:CB</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refers to VWF collagen binding</td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FVIII RAg (FVIII-related antigen)</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Now called VWF:Ag <sup>1</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">RiCof (ristocetin cofactor activity)</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Now called VWF:RCo <sup>1</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Von Willebrand's disease</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Von Willebrand disease</td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">vWD</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWD</td></tr><tr><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">vWF</td><td headers="hd_h_von-willebrand.T.clarifications_and_chan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWF</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VWD = von Willebrand disease; VWF = von Willebrand factor</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.3.1"><p class="no_margin">See <a href="#von-willebrand.Establishing_the_Diagnosi">Establishing the Diagnosis</a>, <b>VWD laboratory assays</b></p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTgeneticdisordersinth"><div id="von-willebrand.T.genetic_disorders_in_th" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Genetic Disorders in the Differential Diagnosis of von Willebrand Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.genetic_disorders_in_th/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.genetic_disorders_in_th_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diagnosis</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>F8</i>
|
|
</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild-to-moderate <a href="/books/n/gene/hemo-a/?report=reader">hemophilia A</a></td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Persons w/low FVIII due to VWD may be misdiagnosed w/hemophilia A.<br />↓ levels of FVIII:C (~2-40 IU/dL) & normal-to-low levels of VWF can be seen in both type 2N VWD & mild hemophilia A.<br />The frequency of bleeding episodes in hemophilia A varies widely, from multiple times per yr to once every 10 yrs.</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Molecular genetic testing can distinguish VWD & hemophilia A. Molecular testing identifies a causative <i>F8</i> variant in >98% of persons w/hemophilia A. <sup>1</sup><br />VWF:FVIIIB assay can also be used to discriminate between type 2N VWD & hemophilia A. <sup>2</sup><br />Both molecular & phenotypic testing have fallibilities in interpretation. <sup>3</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>GP1BA</i>
|
|
</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Platelet-type VWD <sup>4</sup> (PT-VWD) (OMIM <a href="https://omim.org/entry/177820" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">177820</a>)</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PT-VWD is a platelet disorder; platelet transfusion is required for major bleeding challenges.<br />The PT-VWD phenotype is identical to type 2B VWD.<br />In PT-VWD the half-life of VWF is ↓ as a result of ↑ binding to the abnormal GpIbα on platelets, which can often also necessitate VWF replacement treatment.</td><td headers="hd_h_von-willebrand.T.genetic_disorders_in_th_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWD & PT-VWD can be distinguished by molecular genetic testing.<br />Alternately, RIPA mixing assays using plasma & platelets of affected persons & controls to determine which component is defective <sup>5</sup> can be done, but this method is becoming less available.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; FVIII = factor VIII; FVIII:C = factor VIII clotting; MOI = mode of inheritance; RIPA = ristocetin-induced platelet agglutination; VWD = von Willebrand disease; VWF = von Willebrand factor; VWF:FVIIIB = VWF factor VIII binding; XL = X-linked</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.4.1"><p class="no_margin">
|
|
<a class="bibr" href="#von-willebrand.REF.johnsen.2022.2022" rid="von-willebrand.REF.johnsen.2022.2022">Johnsen et al [2022]</a>
|
|
</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="von-willebrand.TF.4.2"><p class="no_margin">VWF:FVIIIB assay determines ability of VWF to bind FVIII; it is available although on a limited basis.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="von-willebrand.TF.4.3"><p class="no_margin">
|
|
<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al [2021]</a>
|
|
</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="von-willebrand.TF.4.4"><p class="no_margin">One study identified pathogenic variants in <i>GP1BA</i> in up to 15% of persons diagnosed with type 2B VWD [<a class="bibr" href="#von-willebrand.REF.hamilton.2011.501" rid="von-willebrand.REF.hamilton.2011.501">Hamilton et al 2011</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="von-willebrand.TF.4.5"><p class="no_margin"><a class="bibr" href="#von-willebrand.REF.othman.2016.411" rid="von-willebrand.REF.othman.2016.411">Othman et al [2016]</a>, <a class="bibr" href="#von-willebrand.REF.fu.2024" rid="von-willebrand.REF.fu.2024">Fu et al [2024]</a></p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTvonwillebranddisease1"><div id="von-willebrand.T.von_willebrand_disease_1" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Von Willebrand Disease: Recommended Evaluations Following Initial Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.von_willebrand_disease_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hematology</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ensure complete & modern VWD eval has been performed whenever possible prior to invasive procedures or other hemostatic risks.</div></li><li class="half_rhythm"><div>Assess history of bleeding.</div></li><li class="half_rhythm"><div>Assess VWF levels.</div></li><li class="half_rhythm"><div>Assess FVIII levels.</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very old or historical diagnoses of VWD w/o recent laboratory confirmation should not be relied upon in treatment planning.</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">VWF inhibitor testing (when available) in those w/type 3 VWD or suspected presence of inhibitors</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">CBC; iron studies incl ferritin</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for anemia & iron deficiency to identify persons who should have iron replacement</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Musculoskeletal</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Joint & muscle eval (as would be done for persons w/<a href="/books/n/gene/hemo-a/?report=reader">hemophilia A</a>)</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In those w/low FVIII levels or clinical suspicion</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Gynecology</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gynecologic eval for those w/heavy menstrual bleeding &/or ovarian hemorrhage (See also <a href="#von-willebrand.Pregnancy_Management">Pregnancy Management</a>.)</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for other anatomic contributors to bleeding & to coordinate mgmt w/hormonal therapies, IUD, & procedures if needed</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Gastrointestinal</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Endoscopic eval for anatomic causes of bleeding, incl angiodysplasia in those w/suspected GI bleeding</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Infectious disease</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Screening for hepatitis B, hepatitis C, & HIV</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In persons who received blood products or plasma-derived clotting factor concentrates prior to 1985 or w/other risk factors</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genetic counseling</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">By genetics professionals, <sup>1</sup> incl assessment of family history of bleeding to help identify relatives at risk for VWD</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To obtain a pedigree & inform affected persons & their families re nature, MOI, & implications of VWD to facilitate medical & personal decision making</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CBC = complete blood count; FVIII = factor VIII; IUD = intrauterine device; MOI = mode of inheritance; VWD = von Willebrand disease; VWF = von Willebrand factor</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.5.1"><p class="no_margin">Medical geneticist, certified genetic counselor, certified advanced genetic nurse</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTtargetedtherapybyvon"><div id="von-willebrand.T.targeted_therapy_by_von" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Targeted Therapy by von Willebrand Disease Type</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.targeted_therapy_by_von/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.targeted_therapy_by_von_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">VWD Type</th><th id="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment w/VWF replacement is often required for moderate or severe hemostatic challenges & may be required for minor challenges.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Use of VWF replacement depends upon VWF levels & bleeding risk.</td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Desmopressin can be used for minor & some moderate, time-limited (2-3 days) hemostatic challenges in responsive persons.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Responsiveness to desmopressin is variable & should be confirmed prior to therapeutic use.</td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2A</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment w/VWF replacement is usually required for moderate or severe hemostatic challenges & may be required for minor challenges.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Desmopressin response is usually poor.</td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">2B</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment w/VWF replacement is usually required for moderate or severe hemostatic challenges & may be required for minor challenges.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Desmopressin response is usually poor. Treatment w/desmopressin can precipitate or worsen thrombocytopenia in many but not all persons w/type 2B VWD. <sup>1</sup></td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Platelet counts should be monitored, as platelet transfusions may need to be added to VWF replacement.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2M</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment w/VWF replacement is usually required for moderate or severe hemostatic challenges & may be required for minor challenges.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Desmopressin response is generally poor.</td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2N</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment w/VWF replacement is usually required for moderate or severe hemostatic challenges & may be required for minor challenges.</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Because the FVIII levels are low, a VWF replacement product containing VWF as well as FVIII is preferred in initial treatment over a product containing VWF alone.</div></li><li class="half_rhythm"><div>Desmopressin response is generally poor.</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Treatment w/VWF replacement is usually required for moderate or severe hemostatic challenges & is often required for minor challenges.</div></li><li class="half_rhythm"><div>Many individuals require prophylaxis w/VWF replacement to prevent musculoskeletal bleeding & subsequent joint damage.</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.targeted_therapy_by_von_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Because the FVIII levels are low, a VWF replacement product containing VWF as well as FVIII is preferred in initial treatment over a product containing VWF alone.</div></li><li class="half_rhythm"><div>Desmopressin is not effective.</div></li><li class="half_rhythm"><div>Some persons w/type 3 VWD can develop alloantibodies (inhibitors) against VWF.</div></li></ul>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">FVIII = factor VIII; VWD = von Willebrand disease; VWF = von Willebrand factor</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.6.1"><p class="no_margin">
|
|
<a class="bibr" href="#von-willebrand.REF.federici.2009.526" rid="von-willebrand.REF.federici.2009.526">Federici et al [2009]</a>
|
|
</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTvonwillebranddisease2"><div id="von-willebrand.T.von_willebrand_disease_2" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Von Willebrand Disease: Treatment of Manifestations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.von_willebrand_disease_2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hematologic</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fibrinolytic inhibitors (i.e., tranexamic acid, aminocaproic acid) for treatment or prevention of bleeding episodes & as adjunctive therapy for invasive procedures</div></li><li class="half_rhythm"><div>Tranexamic acid can be used alone for minor bleeding <sup>1</sup></div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fibrinolytic inhibitors are relatively contraindicated if there is gross hematuria.</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Epistaxis</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Nasal care (humidity, water-based gels, saline sprays, treatment of allergies or infections), nasal clamps, nasal packing, nasal cautery, VWF replacement</div></li><li class="half_rhythm"><div>VWF prophylaxis for refractive or severe recurrent bleeding</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Treatment w/tranexamic acid (or aminocaproic acid) ± VWF replacement should be considered for frequent bleeding.</div></li><li class="half_rhythm"><div>Treatment should be given prior to cautery.</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Heavy menstrual bleeding</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment options incl:
|
|
<ul><li class="half_rhythm"><div>Hormonal treatments (e.g., combined oral contraceptive pill, progestin-only pills, progestin-only injections, hormonal IUDs)</div></li><li class="half_rhythm"><div>Tranexamic acid (or aminocaproic acid)</div></li><li class="half_rhythm"><div>Desmopressin</div></li><li class="half_rhythm"><div>VWF replacement</div></li><li class="half_rhythm"><div>Combination treatment w/antifibrinolytic &/or hormonal treatment &/or VWD treatment</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Risks & benefits of hormonal therapy should be discussed w/affected person prior to starting treatment.</div></li><li class="half_rhythm"><div>Use of tranexamic acid w/hormonal therapy (in those not desiring pregnancy) or tranexamic acid w/o hormonal therapy (in those desiring conception or w/contraindication) are suggested over desmopressin. Responsiveness to desmopressin should be confirmed prior to therapeutic use. <sup>1</sup></div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Infectious disease</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Encourage vaccination for hepatitis B</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>GI angiodysplasia</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Endoscopic intervention for active lesions (cautery, injection), VWF replacement, tranexamic acid</div></li><li class="half_rhythm"><div>VWF prophylaxis for more severe GI bleeding</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For significant persistent or periodic bleeding from angiodysplasia, also consider adjunctive agents. <sup>2</sup></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">GI = gastrointestinal; IUD = intrauterine device; VWF = von Willebrand factor</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="von-willebrand.TF.7.1"><p class="no_margin">
|
|
<a class="bibr" href="#von-willebrand.REF.connell.2021.301" rid="von-willebrand.REF.connell.2021.301">Connell et al [2021]</a>
|
|
</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="von-willebrand.TF.7.2"><p class="no_margin">
|
|
<a class="bibr" href="#von-willebrand.REF.chornenki.2022.624" rid="von-willebrand.REF.chornenki.2022.624">Chornenki et al [2022]</a>
|
|
</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTvonwillebranddisease3"><div id="von-willebrand.T.von_willebrand_disease_3" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Von Willebrand Disease: Recommended Surveillance</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.von_willebrand_disease_3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.von_willebrand_disease_3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hematology</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Assessment at hematology treatment center w/experience w/bleeding disorders</div></li><li class="half_rhythm"><div>Determination of frequency of bleeding, factors causing incr bleeding, & treatment efficacy & tolerability</div></li><li class="half_rhythm"><div>CBC & iron levels</div></li><li class="half_rhythm"><div>VWF levels</div></li><li class="half_rhythm"><div>Assess for VWD inhibitors in those at risk (type 3 VWD)</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Annually, particularly in those receiving treatment</div></li><li class="half_rhythm"><div>Every 2-3 years in those w/o bleeding & not on treatment</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Musculoskeletal</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Assessment of joint scores & mobility by PT</div></li><li class="half_rhythm"><div>Musculoskeletal ultrasound when applicable</div></li></ul>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In those w/more severe VWD &/or low FVIII levels, or w/evidence of musculoskeletal bleeding, assess on same schedule as <a href="/books/n/gene/hemo-a/?report=reader">hemophilia A</a>.</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Gynecology</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gynecologic eval</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As needed for females w/heavy menstrual bleeding or other reproductive tract bleeding</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Gastrointestinal</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastroenterology eval for iron deficiency, anemia, or signs of GI bleeding</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At time of active bleeding & per gastroenterologist recommendation</td></tr><tr><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Infectious disease</b>
|
|
</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment by specialist in hepatitis B &/or hepatitis C (usually hepatologist) & HIV infection (usually infectious disease specialist); surveillance is disease specific & may incl monitoring viral load, antiviral titer, liver imaging or biopsy, liver function tests, hepatocellular carcinoma surveillance, blood counts, & eval of other comorbidities.</td><td headers="hd_h_von-willebrand.T.von_willebrand_disease_3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As recommended by hepatologist &/or infectious disease specialist in those exposed to blood products prior to 1985 or w/other risk factors</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CBC = complete blood count; FVIII = factor VIII; GI = gastrointestinal; PT = physical therapist; VWD = von Willebrand disease; VWF = von Willebrand factor</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandmolgenTA"><div id="von-willebrand.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Von Willebrand Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_von-willebrand.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_von-willebrand.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_von-willebrand.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_von-willebrand.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_von-willebrand.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_von-willebrand.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_von-willebrand.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/7450" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>VWF</i>
|
|
</a>
|
|
</td><td headers="hd_b_von-willebrand.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=7450" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">12p13<wbr style="display:inline-block"></wbr>​.31</a>
|
|
</td><td headers="hd_b_von-willebrand.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/P04275" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">von Willebrand factor</a>
|
|
</td><td headers="hd_b_von-willebrand.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.vwf.hemobase.com/VWF_Database/Mutations/Mutations.html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EAHAD von Willebrand Factor Database</a>
|
|
<br />
|
|
<a href="https://www.lovd.nl/VWF" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EAHAD Coagulation Factor Variant Databases von Willebrand factor (VWF)</a>
|
|
</td><td headers="hd_b_von-willebrand.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=VWF" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">VWF</a>
|
|
</td><td headers="hd_b_von-willebrand.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=VWF[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">VWF</a>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div id="von-willebrand.TFA.1"><p class="no_margin">Data are compiled from the following standard references: gene from
|
|
<a href="http://www.genenames.org/index.html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">HGNC</a>;
|
|
chromosome locus from
|
|
<a href="http://www.omim.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">OMIM</a>;
|
|
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UniProt</a>.
|
|
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
|
|
<a href="/books/n/gene/app1/?report=reader">here</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobvonwillebrandmolgenTB"><div id="von-willebrand.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Von Willebrand Disease (<a href="/omim/193400,277480,613160,613554" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/193400" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">193400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VON WILLEBRAND DISEASE, TYPE 1; VWD1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/277480" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">277480</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VON WILLEBRAND DISEASE, TYPE 3; VWD3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613160" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613160</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VON WILLEBRAND FACTOR; VWF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613554" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613554</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VON WILLEBRAND DISEASE, TYPE 2; VWD2</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobvonwillebrandTvwfpathogenicvariants"><div id="von-willebrand.T.vwf_pathogenic_variants" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p><i>VWF</i> Pathogenic Variants Referenced in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK7014/table/von-willebrand.T.vwf_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__von-willebrand.T.vwf_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000552.5" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000552<wbr style="display:inline-block"></wbr>​.5</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/NP_000543.3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_000543<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3614G>A</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1205His</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assoc w/type 1C VWD (See <a href="#von-willebrand.Molecular_Pathogenesis">Molecular Pathogenesis</a>.)</td></tr><tr><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.3931C>T</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln1311Ter</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant in Romani population in Spain; homozygotes present w/type 3 VWD [<a class="bibr" href="#von-willebrand.REF.casa_a.2000.552" rid="von-willebrand.REF.casa_a.2000.552">Casaña et al 2000</a>]</td></tr><tr><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4120C>T</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1374Cys</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant in Amish population from Indiana & Ohio, US [<a class="bibr" href="#von-willebrand.REF.gupta.2016.e431" rid="von-willebrand.REF.gupta.2016.e431">Gupta et al 2016</a>]</td></tr><tr><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4414G>C</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp1472His</td><td headers="hd_h_von-willebrand.T.vwf_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common benign variant that causes artificially ↓ results on VWF:GPIbR & VWF:RCo assays</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VWD = von Willebrand disease; VWF = von Willebrand factor; VWF:GPIbR = ristocetin-induced binding of VWF to glycoprotein Ib (GPIb); VWF:RCo = ristocetin cofactor activity testing ability of VWF to agglutinate platelets</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="https://varnomen.hgvs.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/?report=reader">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobvonwillebrandF1"><div id="von-willebrand.F1" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK7014/bin/von-willebrand-Image001.jpg" alt="Figure 1. . An approach to the diagnosis of von Willebrand disease (VWD) [James et al 2021]." /></div><h3><span class="label">Figure 1. </span></h3><div class="caption"><p>An approach to the diagnosis of von Willebrand disease (VWD) [<a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al 2021</a>]. VWF levels refer to VWF antigen (VWF:Ag) and/or platelet-dependent VWF activity of 30-50 IU/dL, with the caveat that the laboratory’s lower limit of the normal range should be used if that limit is <50 IU/dL.</p><p>BS = bleeding score; CBC = complete blood count; DDAVP = desmopressin; FVIII = factor FVIII; FVIII:C = factor VIII coagulant activity; PT = prothrombin time; PTT = partial thromboplastin time; r/o = rule out; TT = thrombin time; VWF:CB/Ag = ratio of VWF collagen binding to VWF antigen; VWF:FVIIIB = VWF FVIII binding.</p><p>Adapted with permission from James et al 2021.</p></div></div></article><article data-type="fig" id="figobvonwillebrandF2"><div id="von-willebrand.F2" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK7014/bin/von-willebrand-Image002.jpg" alt="Figure 2. . Algorithms for additional testing in suspected type 2B von Willebrand disease (VWD) (left) and suspected type 2N VWD (right)." /></div><h3><span class="label">Figure 2. </span></h3><div class="caption"><p>Algorithms for additional testing in suspected type 2B von Willebrand disease (VWD) (left) and suspected type 2N VWD (right).</p><p>GPIb = glycoprotein Ib; RIPA = ristocetin-induced platelet agglutination; VWF:FVIII = von Willebrand factor/Factor VIII ratio.</p><p>Adapted with permission from <a class="bibr" href="#von-willebrand.REF.james.2021.280" rid="von-willebrand.REF.james.2021.280">James et al [2021]</a>.</p></div></div></article><article data-type="fig" id="figobvonwillebrandF3"><div id="von-willebrand.F3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20.%20VWF%20protein%20structure%20and%20location%20of%20VWD-causing%20VWF%20variants%20by%20VWD%20type.&p=BOOKS&id=7014_von-willebrand-Image003.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK7014/bin/von-willebrand-Image003.jpg" alt="Figure 3. . VWF protein structure and location of VWD-causing VWF variants by VWD type." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3. </span></h3><div class="caption"><p>VWF protein structure and location of VWD-causing VWF variants by VWD type. Bold horizontal lines indicate the approximate position of exons where VWD-causing variants are most prevalent; thinner lines indicate exons with variants of lower frequency. VWD-causing variants that result in type 2 VWD affect VWF function and cluster in domains primarily disrupted by missense variants.</p><p>[reprinted with permission from <a class="bibr" href="#von-willebrand.REF.laffan.2021.66" rid="von-willebrand.REF.laffan.2021.66">Laffan et al 2021</a>]</p></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|